OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2024-12-31-accounts

Ensuring no one faces kidney disease alone

Kidney Care UK Trustees’ report and financial statements for the year ended 31 December 2024

The British Kidney Patient Association operating as Kidney Care UK (a company limited by guarantee) Registered number: 1228114 Charity number: 270288 Charity number (Scotland): SC048198

Contents

About Kidney Care UK

Patient Support Services

Improving life for kidney patients

----- Start of picture text -----
2
----- End of picture text -----

Campaigning and patient involvement

Charity management and financial statements

----- Start of picture text -----
“
----- End of picture text -----

Sue Fisher is a kidney patient on dialysis and was struggling with her bills including water. She was in debt with her water company, but after a visit from Kidney Care UK and Wessex and Bristol Water she was helped to get things back on track.

Living with kidney disease has had an impact on so many areas of my life, but especially financially. They asked me how much I could afford to pay each month to reduce the debt, and we settled on an amount that does not overstretch me. On the whole, they were amazing.

Sue Fisher, kidney patient 3

Foreword from our

One in 10 people in the UK have chronic kidney disease (CKD), a lifelong condition with no cure. As we enter our 50th year as the UK’s leading kidney patient support charity, Kidney Care UK has increased our direct support services to patients, engaged with more professionals to improve NHS service delivery and acted as a stable constant presence, offering trusted advice, information and lobbying at a time of turmoil in the NHS. In 2024, highlights included:

2024 was another year of transformation and growth for Kidney Care UK, as we continued to reach and support even more patients and their families. We are determined that everyone affected by kidney disease is aware of the Charity and can turn to us for the advice, guidance and support they need. As a result, and thanks to the generosity of our supporters, we have expanded our services to meet patients’ needs in these challenging times.

To enable this growth, we increased our expenditure on charitable activity by 26%, from £4.5m in 2023 to £5.7m in 2024, all made possible by an increase in fundraised income from £3m in 2023 to £4.1m in 2024, along with our ongoing commitment to responsibly draw down from our capital investments to fund greater patient support.

Life continues to be challenging for kidney patients, and the need for our support grows as we ensure we are there for all the patients and families who need us. We were delighted to embark on a significant expansion of our welfare and wellbeing service, which launched in Wales in 2023 and provides in-depth, personal support for everyone preparing for or receiving treatment for kidney failure.

We were able to more than double the size of our Patient Support & Advocacy team on the ground, increasing our presence in healthcare settings and extending the service to support patients across Scotland, and the north west, north east, south east, and south west of England, providing support to thousands more patients across more than half the UK.

----- Start of picture text -----
4
----- End of picture text -----

and Chair of Trustees,

We also launched a free patient support line, ensuring that patients who reach out to us are able to talk immediately to someone who “gets” kidney disease, as well as working with the London Kidney Network to launch a new regional model of peer support that combines the support of the Charity with healthcare champions in every London hospital.

Our growth wasn’t just about greater personal oneto-one support, as we developed our information and communication channels to ensure people are able to access the information they want in a format that suits them. We launched a new website, resulting in an increase in website visitors of over 40%, to just shy of 1.5 million. Our patient information partnership with the UK Kidney Association also expanded as we sought to ensure high quality, trusted information is available to all patients wherever they receive their care, with over 300,000 leaflets distributed.

Our partnership approach of working with healthcare professionals and organisations to improve kidney services saw a significant development, with the launch of a national quality improvement project — Transform AKC — with the UK Kidney Association (UKKA) and NHS trusts across the UK, to improve the quality of advanced kidney care clinics.

----- Start of picture text -----
5
----- End of picture text -----

The project is designed to improve NHS service delivery at this critical focal point for those with advanced kidney disease, and support patients at this pivotal part of their kidney journey where decisions on pre-dialysis transplantation and access to home dialysis, as well as conservative care where appropriate, are taken following shared decision making.

We continued this strategic theme of reaching people early with the launch of a new national campaign to promote early diagnosis and treatment of chronic kidney disease: #BloodyAmazingKidneys. The campaign both raises awareness and provides patients, via a digital kidney health checker, with the tools to see if they are at increased risk of CKD and to help them feel confident in raising their concerns with their GP. By the end of the year almost 120,000 people had completed a kidney health check.

To support these developments, we have continued to work to ensure our organisation infrastructure is robust enough to accommodate such growth and expansion, that our operation remains efficient to ensure that every pound we are donated is well spent and that our values and staff wellbeing are prioritised to ensure we remain the patient-focused, caring organisation we have always been.

2025 sees Kidney Care UK reach the milestone of our 50th anniversary, and we start the year a bigger, better charity. We may have changed in size as an organisation, but at our heart we are the same Charity started in 1975 by a mother, Elizabeth Ward, who was determined to fight for her son’s care and quality of life. We have achieved a great deal, but we know that there is more to be done to help kidney patients and their families live well with kidney disease. The future remains uncertain and challenging for patients, but with the continued support and generosity of our supporters and staff we aim to celebrate our 50 years by helping more patients than ever before and ensuring no one has to face kidney disease alone.

Paul Bristow, Chief Executive

Dr Graham Lipkin MB ChB, BSc, MD, FRCP (UK) , Chair of Trustees

----- Start of picture text -----
6
----- End of picture text -----

“ 2025 sees Kidney Care UK reach the milestone of our 50th anniversary, and we start the year a bigger, better charity. We may have changed in size as an organisation, but at our heart we are the same Charity started in 1975.

----- Start of picture text -----
“
----- End of picture text -----

Our vision: all kidney patients can live their life to the full

Our mission: to improve the quality of life for everyone affected by kidney disease

Kidney Care UK is the UK’s leading kidney patient support charity, working to improve the quality of life for everyone affected by kidney disease and raising awareness of kidney disease amongst the wider public. We provide practical, financial and emotional support to patients and their families, work in partnership with health professionals and statutory bodies to improve the access and quality of health and care services. We also represent the patient voice in campaigning for change in policy and practice.

A diagnosis of CKD can be devastating, placing a considerable toll on patients and their loved ones. The condition affects every aspect of an individual’s life including physical health, emotional wellbeing, finances and relationships, as well as employment and lifestyle. We work every day to change lives for patients, whatever their age, wherever they are in the UK and at whatever stage of the disease they might be. With our help no one should face kidney disease alone.

8

Irrr i) 657 T/

Trustees statement

The Trustees (who are also directors of the Charity for the purposes of Company Law) present their annual report, which incorporates the directors’ report, the strategic report, and the financial statements of The British Kidney Patient Association (BKPA), operating as Kidney Care UK, for the year ended 31 December 2024.

The annual report and financial statements comply with the Charities Act 2011, the Companies Act 2006, the Memorandum and Articles of Association, and Accounting and Reporting by Charities: Statement of Recommended Practice (SORP 2019) applicable to charities preparing their financial statements in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

Since the charitable company qualifies as medium under section 382, the Strategic Report required of medium and large companies under the Companies Act 2006 (Strategic Report and Directors’ Report) Regulations 2013 is included. The Strategic Report comprises Our impact in 2024, Our Financial Review and Our Principal Risks and Controls. The legal status and governance structure is explained in the “Structure, governance and management” section of this report on pages 68 to 70. The Trustees confirm that they have complied with the duty in Section 17 of the Charities Act 2011 to have due regard to public benefit guidance published by the Charity Commission in determining the activities undertaken by the charity.

Our charitable objects as set out in our articles of association are:

1.

To educate and inform the public regarding all forms of kidney and associated disorders.

2.

To promote the welfare of persons suffering from kidney and renal diseases or associated disorders (“Kidney Patients”) including providing them with financial assistance.

To make grants to hospitals for new buildings and other construction works for kidney units, for facilities for kidney transplantation, dialysis and their renal treatment and to meet cost of employing personnel to provide renal services.

To fund research for the benefit of kidney patients.

----- Start of picture text -----
10
----- End of picture text -----

3.

4.

Kidney Care UK 5 year strategy (2021-2025) Strategic objectives:

To reach and engage more individuals and families living with chronic kidney disease (CKD).

To work in partnership to improve the way kidney patients are cared for across the UK.

To ensure patient views are effectively represented and campaign for better patient care.

To manage our Charity as effectively and efficiently as possible.

To inspire more people to support our work and develop a mature fundraising portfolio.

----- Start of picture text -----
11
----- End of picture text -----

Being there for the kidney

BKPA founder Elizabeth Ward following the Granada TV Appeal in 1978, which achieved a Guinness World Record.

HRH Diana, Princess of Wales, and Elizabeth Ward opening the paediatric renal unit at Yorkhill Hospital, Glasgow in 1983.

----- Start of picture text -----
12
----- End of picture text -----

Elizabeth Ward with Tony Blair, Prime Elizabeth Ward with former Kidney Care UK Photo caption Minister 1997-2007. CEO Paddy Tabor in 2017.

2024 at a glance . £5.6m Morethan Spent on 8.000 charitable activities kidney patients and families helped Printed patient information resources supplied £3.46m 811k invested in staff and care services for patients individuals received helpwith 1.832 .:...,: assistance £608K given in grants to help cope with unexpected bills Over £1.9m 4,800 in benefits income securedforfamilies facing hardship 4.201 patients supported with counselling. debt advice and advocacy fundraisers and supporters making it all possible 14

Almost 120.000 There were people completed our 3.750 online Kidney Health Checker support line users 791 pieces of media coverage with a reach of Wewona partnership award forourcollaboration with Anglian Water atthe Collaboration NetworkAwards 35.4m people 12.966 people in ouronline community, an increase of 8Y The Diary of a Kidney Warrior Podcastwon the GXAward for Best Podcast and saw a 410A increase in downloads Our supporters raised over £3.3m Oursocial media audience grew by to support people living with kidney disease, an increase of 43Y 21/ 15

How our services supported patients

Kidney disease affects more than 7 million people in the UK, equivalent to 1 in every 10 people, with around half of those living with the more advanced stages of chronic kidney disease (CKD). Kidney disease impacts all aspects of life, with individuals living with the disease more likely to be economically disadvantaged, and more likely to experience low mood and depression.

----- Start of picture text -----
16
----- End of picture text -----

How we spent our funds

The demand for our support has never been greater, which is why we want to reach and engage with as many people as possible. We help them understand what a diagnosis of kidney disease means to them and their loved ones, as well as providing the emotional, financial and practical support they need to be able to live with a condition that has no cure.

----- Start of picture text -----
17
----- End of picture text -----

Patient Support Services

Information, advice and guidance through our Patient Support & Advocacy service

2024 was a transformational year for the Patient Support & Advocacy service, thanks to funding secured through our Gas Distribution Network Partners (Cadent, SGN, Wales and West Utilities and Northern Gas Networks) for our Safe and Warm programme. The expansion of the service builds on the experience of working with the Welsh Kidney Network to embed welfare and wellbeing support for dialysis patients across Wales, made possible with the generous support of Wales & West Utilities, which since its inception in 2023, has successfully helped more than 1,700 patients across Wales.

We were delighted to extend this model of support to Scotland and several regions in England covering a patient population of nearly 9,000 dialysis patients. To deliver welfare and wellbeing support we recruited a brilliant group of new professionals, bringing our frontline team to 28, supported by a new regional management team of six.

Across the UK, the service retains its clear focus on ensuring that patients have access to help at every stage of their diagnosis and treatment, providing vital financial, practical and emotional support. Our team have established strong working relationships with treatment centres nationwide, connecting with patients regularly in kidney clinics.

Our expanded service has allowed us to take our support directly to the patient community, ensuring they not only receive the help they need but also are aware of the further support offered by Kidney Care UK should it be needed in the future. Whether answering a simple question or working alongside patients over time to address complex needs, the Patient Support & Advocacy service has delivered critical, life changing support to more people in 2024, and will continue to do so in the years ahead.

----- Start of picture text -----
18
----- End of picture text -----

After his kidney disease diagnosis in 2022, Lee felt like he had no support and at one point was made homeless. Lee contacted the Patient Support & Advocacy service, and his Patient Support Officer referred him to extra support with debt after he had to stop work, helped him secure food parcel vouchers from his local food bank, and supported him to secure safe accommodation.

“

I was that low psychologically that if Kidney Care UK hadn’t been there, I would have stopped taking my medication and I would have opted out of dialysis. If you are having a bad day, ring up Kidney Care UK and they will help you. You are not alone. Thank you to everyone at the Charity.

Lee In 2024 there were new patient 4,546 referrals to our service, an increase of 37% compared to 2023

----- Start of picture text -----
19
----- End of picture text -----

Patient Support Services

Our Specialist Money & Energy Advice service guides patients from financial crisis to stability

This year, building on the specialist Money & Energy Advice service introduced in 2023 at the peak of the cost-of-living crisis, we have responded to the increasing demand for support to navigate welfare benefits, income maximisation and energy efficiency guidance with significant growth in the service. The team works remotely with patients, guiding them from financial crisis to stability, by providing expert advice. The Money & Energy Advice service helps patients access all the welfare benefits they are entitled to.

With ongoing support from British Gas Energy Trust and new advisers funded by the Gas Distribution Networks , we’ve increased our reach, delivering vital financial support to more vulnerable individuals across the UK. This expansion has enabled the Charity to develop a comprehensive model of financial support, shaped around individual needs of patients.

Alongside our free online self-help tools (Benefits Calculator and Personal Independence Payment Helper) and our Patient Support & Advocacy Officers, the Money & Energy Advice Service plays a crucial role in ensuring patients are connected to the right support at the right time. Our advisers empower individuals to secure the support they are entitled to, giving them greater financial stability. Once that foundation is in place, we offer further assistance, helping patients review utility tariffs and access energy saving guidance to reduce everyday living costs.

At a time when the cost of living impacts the patient community more than most, this support has never been more critical. Thanks to our dedicated service funding, we have also been able to provide practical assistance, distributing electric blankets to keep patients warm during the winter months and energy saving light bulbs to help reduce fuel costs, ensuring those in need receive direct, tangible help.

£1,890,431 financial gains realised across all financial support mechanisms

----- Start of picture text -----
20
----- End of picture text -----

----- Start of picture text -----
“
----- End of picture text -----

Andrew Harris was diagnosed with kidney failure in 2021 and had to give up his business. He lived off his savings until they ran out. With money worries mounting, he contacted Kidney Care UK.

Kate, his Money & Energy Adviser, discovered he was not on the Priority Services Register (PSR) for any of his utility suppliers. She also identified benefit payments Andrew was entitled to, the first being Personal Independence Payment (PIP). Kate helped Andrew complete the form and talked him through what to expect when he received his assessment date.

Andrew’s PIP application was successful and he was awarded the PIP standard daily living component and enhanced mobility, with a backdated payment. Andrew also applied for Universal Credit and was awarded the standard allowance and ‘limited capacity for work-related activity’ allowance. He was able to claim Council Tax Support, which has seen his bill reduce substantially. In total, with Kate’s help, Andrew will be better off by £19,100 a year.

Applying for PIP was particularly stressful and I couldn’t deal with it on my own. I’ve always been someone who is able to sort things out but felt quite overwhelmed by this. Kate has been brilliant and is always there to help me. She’s taken a huge weight off my shoulders, so now I can focus on dialysis instead of worrying about money. Andrew Harris

----- Start of picture text -----
21
----- End of picture text -----

Patient Support Services

Establishing a new vital Peer Support service

The opportunity to speak with someone else who has been through what you are facing offers information, comfort and hope. When patients are diagnosed or embarking on a new treatment, speaking to someone who shares tips about what they take from home to make their dialysis more comfortable, for example, or things they do to protect their fistula, really prepares patients for meeting the challenges with a positive approach.

The successful launch of our Peer Support service this year has created new opportunities for people to seek information and support. Responding to demand from patients, carers and kidney health professionals, the pilot service, delivered in partnership with the London Kidney Network, has been well received across the London area and plans are being developed to extend it to the rest of the country. The Peer Support service offers people living with kidney disease the chance to be supported by someone who has lived experience of kidney disease and who knows what they are going through. We also support family members, carers and donors.

The Kidney Care UK Peer Support service provides comprehensive training for volunteers, following a UK Kidney Association-endorsed programme, managing the onboarding process to ensure safeguarding and support is robust for both volunteers and service users. All matches are made personally and followup with peer support recipients ensures any further questions or support are addressed to enable them to make choices about their treatment and lifestyle based on sound knowledge and improved confidence.

In 2024 there were 162 referrals for peer support received both directly and from renal care staff in the first six months of the service

----- Start of picture text -----
22
----- End of picture text -----

“

Martin [ m y peer supporter] was truly an excellent listener and we got on very well. He asked me to tell him a bit about me and my situation and we went from there, he empathised with me. He was able to explain in more personal detail how home haemodialysis works and what the drawbacks and positive parts were to it.

What was especially important to me was having someone non-judgemental to talk to, who understood what worried me. The chance to actually talk about things properly in “non-doctor speak” was so rewarding and was extremely helpful.

Peer support recipient who was supported by Martin (pictured)

Patient Support Services

Emotional support thorough our dedicated free Counselling service

With resources for psychosocial support in the NHS under more pressure than ever, our specialist renal counselling service offers a lifeline to those meeting the challenges of living with CKD. The people we support continue to express great relief and appreciation that they are able to speak to professional counsellors who have a good understanding of this gruelling and cruelly uncertain disease. Our service offers Zoom, Teams, WhatsApp or telephone counselling sessions; we’re happy to use whichever channel suits the person we are supporting.

Demand for our service remains high, with over 1,500 counselling sessions delivered in 2024, despite not having the benefit of a full complement of counsellors. This undoubtedly impacted the number of patients we were able to support, but we were able to welcome new counsellors to the team towards the end of the year and have already begun to redress the deficit.

In response to the growing demand for psychosocial support we are exploring different ways in which we can empower people to manage their emotional wellbeing and build personal resilience. A successful group session pilot carried out this year demonstrated that a counsellor-facilitated online group setting delivers real benefits to people presenting with common challenges, such as managing anxiety. Feedback from participants highlighted how accessing a safe space for sharing experiences and peer networking was beneficial to their confidence and improved feelings of wellbeing. In future we look forward to welcoming new clients into forums to address a variety of common challenges.

In 2024 we ran

1,544 counselling sessions, supporting 273 people affected by kidney disease

----- Start of picture text -----
24
----- End of picture text -----

“

Our counselling team are exploring different ways in which we can empower people to manage their emotional wellbeing and build personal resilience. We’re looking at how we can deliver more counsellor facilitated group online sessions after a successful pilot as feedback highlighted that sharing experiences and networking with peers was beneficial to building confidence and improved feelings of wellbeing

Jackie Pilcher, Lead Counsellor, Kidney Care UK

----- Start of picture text -----
25
----- End of picture text -----

Patient Support Services

Patient grants to help people with kidney disease live life to the full

Since the Charity’s inception, our patient grants service has been there to help people to navigate the challenges of living with kidney disease and the impact it can have on every aspect of your life. We continue to be proud to offer grants to patients, when sometimes just a little financial support can make a huge difference - whether they need a replacement fridge-freezer or a respite break away from the routine of treatment. It is heartening to see that, after the pandemic, our community are now feeling more confident about taking much-needed breaks, with nearly twice as many requests for assistance with holidays.

We provided a holiday grant of £480 to help Sharon and her husband have a short break with their grandchildren. The chance to have a few days away making memories is priceless.

“Thank you very much for a fantastic holiday. Even if it was just for a weekend, it made a difference to me because being on dialysis it’s hard to live a normal life. I’m so grateful to Kidney Care UK. Sharon In 2024 we gave £917,621

to people affected by kidney disease, the highest number of grants and amount we’ve awarded in the last decade

----- Start of picture text -----
26
----- End of picture text -----

Individual patient grants given in 2024

Holiday grants increased by 69% compared to 2023, as people’s confidence in travel returned.

----- Start of picture text -----
27
----- End of picture text -----

Patient Support Services

The chance to have a break, through the Kidney Care UK Dialysis Freedom service

We continued to work extremely hard to enable as many patients as possible to access dialysis away from their regular hospital unit so that they can have a holiday in the UK, attend events, work, and visit family and friends. We received 2,236 requests for support in arranging Dialysis Away From Base (DAFB) in 2024 and were delighted to be able to confirm bookings for more than 1,000 patients (1,091).

Considering the limitations of access to DAFB across the UK, we are still managing to help hundreds of patients every year. As well as support to make a booking, we often give patients and home units advice and guidance on the DAFB process, the options available, funding, insurance and much more.

DAFB in the UK is still limited, mainly due to capacity and staffing within units. We currently have 41 units across the whole of the UK considering DAFB and 80 units considering requests via the swap scheme only (which is when one of their own patients is away, thus utilising an ‘empty’ space). With every booking we make (unless a home patient), we request that the travelling patient’s slot be made available to our ‘swap scheme database’ to try to improve DAFB places. For some areas in the UK, this is the only way to access space.

We’re pleased to say that 2024 has seen the highest positive answer for the swap scheme postpandemic.

We had 924 requests for Dialysis Away From Base confirmed and booked in 2024 And 167 bookings made in 2024 for travel in 2025

----- Start of picture text -----
28
----- End of picture text -----

“

It was all very well organised, both caring and professional. It was easy to arrange and the person I spoke to at Kidney Care UK Dialysis Freedom explained everything that I needed to do. The holiday centre was excellent, very friendly and my husband felt at ease during his dialysis treatment. Thank you very much, we couldn’t ask for anything better. Kidney Care UK Dialysis Freedom service user

Patient Support Services

Launch of free dedicated Support Line service providing reassurance and trusted advice

Providing valuable information and trusted advice from our knowledgeable team, the launch of the Kidney Care UK free Support Line in August 2024 has transformed the experience for anyone seeking support for the challenges of living with CKD. In its first few months of operation, the Support Line has provided information and reassurance to 3,750 people.

The Support Line offers a friendly ear to listen to concerns, answer queries and to refer on to other services should the caller need further help, reassuring patients that talking to someone who cares and understands what it is like to live with kidney disease is just a call away.

Patients have told us that the service has:

They have also told us that their attitude towards their diagnosis has improved because of the positive conversations they’ve had with our team.

Looking forward, we are excited to build on the successes of the Support Line service and to help more kidney patients and their loved ones needing assistance.

In 2024 we supported

3,750 patients

and loved ones through our Support Line

----- Start of picture text -----
30
----- End of picture text -----

Mary* called the Support Line. She has CKD stage 3b. Mary struggles to talk about how she is feeling, has financial difficulties and is worried about the future.

“ Thank you so much for everything. I really felt heard and appreciated all the advice. Talking to you has been a massive blessing and helped me understand more about my kidney disease. I was looked after so well, many thanks.

Mary

Patient Support Services

Supporting young adults through our online community and residential weekend

Kidney disease is especially difficult for young people at what is already a particularly challenging time in their lives. Having the opportunity to interact with other young adult patients is crucial for those who are transitioning from paediatric kidney care to an adult unit. It allows them to “see where they are going” and learn from slightly older peers who have had a successful and positive transition experience and who are building good working relationships with their new kidney teams, with a positive outlook for the future.

In January 2024 we extended membership of Kidney Care UK’s National Young Adult Kidney Group to young people aged 16 and 17 years old. We now offer support to young adults aged 16 to 30. We are working to improve the support we provide to our younger young adults, ensuring it’s age appropriate and easily accessible.

To supplement the advice and information provided by our 1,200-strong Facebook group and the work of the Peer Support team, we have been able to offer a series of webinars to group members in 2024. Requested by members of the group, these sessions have been on the subjects of work and employment, anxiety management and fundraising to support Kidney Care UK.

The webinars have created space for young people to ask questions in a supportive environment, as well as to contribute their own experiences and expertise as speakers or panel members.

In September 2024 we hosted our largest Young Adult Residential Weekend yet, with an amazing 89 young adult participants from England, Scotland, Wales and Northern Ireland travelling to Mount Cook Adventure Centre, ready to take part in a fun-filled weekend of outdoor activities, workshops and relationship building with peers from across the UK. Over half the group were first-time attendees, which is testament to the success of the weekend and the strong reputation it has developed.

----- Start of picture text -----
32
----- End of picture text -----

Shuaib joined the Young Adult Kidney Group in 2020, looking for support and a community to be part of. Since then, he has also taken advantage of opportunities to give something back to our community. He’s a peer supporter, residential weekend volunteer and has established a small group specifically for male members.

“

Having experienced this journey as a young adult in 2023 and then as a Peer Support Volunteer in 2024, I find this residential weekend to be a heart-warming reminder of the strength found in community. Connecting with resilient young adults facing kidney disease made every moment inspiring and deeply rewarding.

Shuaib In 2024 we had 89 young adult residential weekend attendees, the largest ever cohort of young adults attending the residential weekend

----- Start of picture text -----
33
----- End of picture text -----

Patient Support Services

Patient information: providing patients with accessible, trustworthy and empowering information

Our patient information service – a critical element of our service portfolio – built on its Patient Information Forum (PIF TICK) accreditation in 2023 and saw unprecedented demand in 2024, our busiest year yet for patient information distribution. This growth was made possible by a move to outsourced fulfilment and online ordering through the new website, streamlining the ordering process and ensuring that most orders are sent out within a week. The team were extremely busy, fulfilling 317,515 leaflet requests from 2,433 clinical settings across our suite of more than 50 brochures and leaflets. Overall demand grew 100% year-on-year (in 2023 we fulfilled requests for 158,922 leaflets).

In 2024 we saw continued growth in requests for our resources, both in print and online, as well as completion of the redesign and update work started in 2023. Working with the UK Kidney Association (UKKA), we completed our review of all 56 titles and are delighted that they are all now updated and PIF TICK accredited, providing reassurance of their quality to patients and professionals.

Healthcare professionals are increasingly using our patient information materials to support and empower patients in understanding their kidney disease. These resources help individuals make informed choices about their treatment, enabling them to take a more active role in their care. Looking ahead we will continue to expand our range of leaflets and work with healthcare professionals to provide greater access to our materials, putting patients at the heart of what we do.

In 2024 we sent out

317,000 patient information leaflets

----- Start of picture text -----
34
----- End of picture text -----

“ My colleague has been corresponding with you for your CKD literature. It is really fantastic, easy to read and laid out well. I talk through the main chronic kidney disease information at events with local residents before they take it away. Healthcare professional from Sutton Primary Care network

----- Start of picture text -----
35
----- End of picture text -----

Patient Support Services

Kidney Kitchen: ensuring delicious food is back on the table when you have kidney disease

When we think about health beyond medicine, the success of the Kidney Kitchen continues to grow, with 378,000 unique visitors coming to the website for dietary information and advice – a 35% increase on 2023 traffic. This also translates into total print order numbers across our four Kidney Kitchen recipe magazines, which now exceed 40,000, a superb achievement from a standing start back in 2021 and an indication of the level of demand that exists for high quality, trusted dietary information when you are coping with the demands of a restrictive kidney diet.

We welcomed more guest chefs into the kitchen to create kidney-friendly dishes with Chef Ripley, notably Lai Man and her father, Kim. The ‘Wonton with tossed noodles’ recipe then formed part of a Kidney Kitchen masterclass Chef and Lai gave at the Young Adult Kidney Group Mount Cook Residential Weekend to an enthusiastic group of young adult kidney patients. And once again this year, the entire Mount Cook Young Adult Weekend menu was based on recipes provided by the Kidney Kitchen.

“ I am a huge Kidney Kitchen fan; I find the recipes really helpful with managing my diet and I love exploring new recipes. Saturdays are my Kidney Kitchen days at home, and it’s my day to cook for everyone else.

Young chef Charlie Friedland, who cooked in the Kidney Kitchen with us

In 2024 there were

378,000

unique visitors coming to the website for dietary information

----- Start of picture text -----
37
----- End of picture text -----

Patient Support Services

Giving people with kidney disease access to the best online information, tools and support

Our digital engagement went from strength-to-strength in 2024. We had a fantastic 1.49 million unique visitors to the website, up from 1 million unique users in 2023 (a 42% increase year-on-year), due to the excellent efforts of our Web & Digital team who developed digital content and hubs to promote our support services. Looking back to 2021, we had a total of 673,160 unique visitors to the website. Put simply: the growth and profile of the Charity is increasing sharply because of our desire to ensure that everyone who could benefit from our support is aware and able to access it. Subscriptions to our email newsletter grew to a record 28,838, up from 16,810 at the end of 2023 (a 72% increase).

Accessibility, ease of use and eye-catching design continue to drive our content publishing schedule, with approximately 70% of our website traffic now on mobile devices. Our email programme allows us to communicate with people who have signed up to hear from us and share information and news that is useful and relevant for everyone affected by CKD. In 2024, we emailed our mailing list every week with updates about treatments, policy campaigns, patient services and fundraising and volunteering opportunities.

In February we updated the infoKID website for the parents and carers of babies and children with CKD, produced in partnership with the British Association for Paediatric Nephrology. In July we produced a new website for our Shared Haemodialysis Care programme, which engages patients as active partners in their treatment.

New digital tools developed in 2024 make it easy for people to understand their risk of developing kidney disease, check their benefits entitlement and contact their MP. With almost 120,000 completions in 2024, the Kidney Health Checker (https://kidneycareuk.org/kidney-health-checker/) is the cornerstone of our #BloodyAmazingKidneys awareness campaign and continues to drive incredible engagement, educating people about their kidney health and helping them discuss their CKD risk with their GP. You can read more about this campaign on page 50.

The free Kidney Care UK Benefits Calculator (https://kidneycareuk.entitledto.co.uk/) allows our users to understand the benefits and financial support they may be entitled to when they are living with kidney disease. In 2024, 5,510 users completed a Benefits Calculator calculation. Our free PIP Helper offers step-by-step guidance from the Kidney Care UK Patient Support & Advocacy team for people who are applying for Personal Independence Payment (PIP). The Helper had 3,835 users in 2024.

----- Start of picture text -----
38
----- End of picture text -----

----- Start of picture text -----
“
----- End of picture text -----

[The website information] reads well, is simple to understand and not scary. It’s clear and informative. I wish I’d been directed to read this [when] I was diagnosed. I got a letter from a GP... and my first Google search told me I was going to die! Feedback received via email

In 2024 there were

1,499,645

users of the Kidney Care UK website

----- Start of picture text -----
39
----- End of picture text -----

Patient Support Services

Educating and informing people through our regular Kidney Matters magazine

Our 2023 Kidney Matters readers survey clearly demonstrated a request for ‘more of the same please’ – more insightful, lived patient experiences, more trustworthy healthcare professional advice and more signposts to the help and support available from Kidney Care UK.

We started 2024 with a new, talented and ambitious Kidney Matters design and editorial team with a remit to enhance the magazine’s appeal to everyone affected by kidney disease. In the last twelve months this approach successfully stimulated an increase in individual sign-ups to receive Kidney Matters at home to 12,188 (December 2024 data) – an increase of 39% on 2023.

As the leading kidney patient magazine in the UK, Kidney Matters also works hard to cultivate relationships with related healthcare charities. One such charity, the PKD Charity, supported a piece in the autumn issue on the use of tolvaptan, a drug which can help maintain kidney function in some patients with polycystic kidney disease (PKD). A successful inter-charity collaboration acknowledged by Jane Pugh, PKD Charity Communications Manager, “I wanted to extend my sincere thanks for the outstanding coverage. It’s rare for PKD to receive such in-depth attention, and raising awareness is crucial for improving education and advancing research for the thousands affected by this condition. Thank you again for your continued support.”

----- Start of picture text -----
40
----- End of picture text -----

In 2024 there were

12,188 individual sign ups to receive Kidney Matters magazine

One of the most striking and heart-warming stories we covered in Kidney Matters was that of a young Ukrainian man, Mykola, who, forced to flee his war-torn home where accessing safe dialysis was no longer possible, trekked unaccompanied across Europe facing unimaginable difficulties en route, to reach the safety of Scotland – the place he now considers home. Mykola is now an active member of our Kidney Care UK Young Adult Kidney Group (YAKG) and joined us at the 2024 Mount Cook YAKG residential weekend.

----- Start of picture text -----
41
----- End of picture text -----

Working in partnership to improve the

Since 1975, Kidney Care UK has been working in partnership with health and care professionals, as well as patient organisations, to support service improvements and innovation in patient care and to ensure that the views and involvement of patients are at the forefront of all local and national service developments and quality improvement work.

Investing in improvements to kidney care through our Hospital Grants programme

Over the last fifteen years the charity has provided over £10 million in funding for 70 hospital renal units around the UK, as well as providing grants to patient organisations, professional associations and other key projects that support improvements to access and quality of patient care services. In 2024 our ongoing investment commitments stood at around £500,000, and in 2024 we agreed to award a further 44 new grants totalling an additional £456,636. Highlights included:

A new holiday caravan for South East Scotland KPA

We have replaced the Caravan at the Berwick Holiday Centre so that members of the South East Scotland Kidney Patient Association (SESKPA) and Fife Kidney Patient Association are able to get a much-needed break.

An exercise bike to help patients at Shrewsbury and Telford NHS Trust

This machine allows haemodialysis patients the opportunity to undertake exercise whilst undergoing treatment. If assessed to be suitable these individuals will have a moderate exercise plan developed to help them maintain strength and health over a number of months.

Helping 18 teams take part in the 2024 Transplant Games

As well as providing funding to support 18 teams from across the UK to attend the British Transplant Games in Nottingham, we were once again one of the lead sponsors of the Games.

A national partnership with the UKKA to improve early care

A three-year national programme, in partnership with the UK Kidney Association, to improve Advanced Kidney Care Clinics.

----- Start of picture text -----
42
----- End of picture text -----

Investing in a major national change programme through our Advanced Kidney Care Clinics project, Transform AKC

A significant investment via our Hospital Grants Programme has been the development of the Advanced Kidney Care Clinics project, Transform AKC, run in partnership with the UKKA. This is a major three-year national programme of change, with an aim of improving equity of access to the highest quality care and driving system wide, sustainable change in the support and preparation of patients as they approach kidney failure.

The project will see five pilot sites from across the UK recruited to create an Advanced Kidney Care toolkit and patient support package which puts the patient at the heart of the clinics, as well are creating a community of professionals who can champion change. Through a series of webinars, face-to-face summits and group working, the project aims to standardise the variation in Advanced Kidney Care across the UK and facilitate change.

The programme has major ambitions and aims to:

----- Start of picture text -----
43
----- End of picture text -----

Putting the patient voice at the

The Kidney Patient Reported Experience Measure (PREM)

We believe the patient voice must be at the heart of quality improvement, which is why the Kidney Patient Reported Experience Measure (PREM) survey is such an important piece of work. The 2024 kidney PREM was the ninth PREM survey we have released, in partnership with the UK Kidney Association (UKKA) and supported by the University of Hertfordshire.

The survey was completed across eight weeks in autumn 2024, and asked people to rate 13 key themes with a score out of seven, as well as allowing patients to add their own personal comments on the care they receive, which we ensure are fed back to their healthcare team. This year we received the highest number of responses since 2019, with 13,347 completions. Of the 13 thematic questions, the questions about privacy and dignity received the highest score (indicating approval), and transport received the lowest score.

As well as helping us see how units are performing year on year, it is crucial that the feedback we receive is actively utilised by units. Therefore, we introduced “you said, we did” posters, and encouraged units to display these on their wards to show their patients how they are listening to their feedback and using it to improve the care provided.

----- Start of picture text -----
44
----- End of picture text -----

In 2024 13,347 PREM surveys were completed, the highest completion rate in five years

----- Start of picture text -----
45
----- End of picture text -----

Putting the patient voice at the

Empowering patients to take more control and play a shared role in their care

Kidney Care UK has been instrumental in driving and supporting greater uptake of Shared Haemodialysis Care since 2017, and we remain committed to helping empower patients to be in more control, become partners in their own care and improve their confidence and health outcomes.

Our funding and support for the national accredited training programme continues to train hundreds of healthcare professionals and teams right across the UK and following the publication of the NHS GIRFT (Get it Right First Time) report the interest in Shared Care and the development of a greater learning culture in units has significantly increased.

In 2024 we brought the programme and resource in house and hosted it on a new, bespoke website, as well as developing a distinct Shared Haemodialysis Care brand look and feel. We are pleased with the growing traffic on the Shared HD Care website with 1,400 unique users and 5,044 page views since launch (24 July 2024). We will continue to update and develop the training resources with the new branding, supporting the growing community of practice and continue promoting the Shared Care course and resources to healthcare professionals in 2025.

----- Start of picture text -----
46
----- End of picture text -----

Empowering patients to take more control and fit their healthcare around their lives through the national DAYLife project

As a founding member of the national DAYLife programme (Dialysis at Yours, Life Fulfilled), 2024 saw us continue to work in partnership to increase the rates of home dialysis in the UK, giving patients greater control over their care and improving their quality of life. Our aim remains for all kidney centres to achieve a minimum of 20% of their patients on home dialysis.

The DAYLife project continued in 2024, and we were delighted to welcome the National Kidney Federation (NKF) as a new partner in the programme, joining ourselves, the UKKA and Fresenius Medical Care. Following feedback from patients and healthcare professionals, we established four core national workstreams, all designed around the key elements needed to support greater levels of home care:

The programme included a Home Dialysis Summit and webinars for both health professionals and patients promoting shared care and peer support. The DAYLife Knowledge Hub was created and is now a central resource for all healthcare professionals to help them promote home therapies and discuss ideas with others in the field.

----- Start of picture text -----
47
----- End of picture text -----

Policy and Campaigns

Ensuring patients’ views are effectively represented and campaigning for better care

Championing the issues that matter most to our kidney patient community

The patient voice is at the heart of everything we do. It is the most important part of our work to influence and campaign for change. We’re fortunate to have many people willing to share their perspective and experience of chronic kidney disease and kidney failure. These people include patients, carers, family members and living kidney donors. Their insights are critical, providing credible and authentic insight that shapes and informs our work, and Kidney Care UK engages with thousands of patients every year.

Influencing policy and campaigning for change

Our Policy team is dedicated to making sure the voices of kidney patients are heard by politicians and policy makers, to help them understand the challenges kidney disease can bring and develop the policy framework that drives health and care practice in our NHS and social care services and interventions. Whether bringing people with kidney disease to our national Parliaments or seeking their views on key issues like prevention of CKD, our campaigns are fuelled by what the kidney community tell us they need. With so much change in the health service it was a busy year with work across all four UK nations and themes covering early diagnosis and prevention, organ donation and transplantation, transport and the cost of living.

Home dialysis – getting your energy costs repaid

In February 2024, following our campaigning, the Scottish government introduced national guidelines for energy reimbursement for home dialysis in Scotland. Jenni Minto MSP, Minister for Public Health and Women’s Health, made the announcement at a roundtable on the cost-of-living crisis for people with CKD in Scotland, led by Kidney Care UK and hosted by Miles Briggs MSP. This was followed in October by confirmation that, as a result of our campaigning, future reimbursement payments in Northern Ireland would cover peritoneal dialysis as well as home haemodialysis.

Improving transplantation experiences and organ donation rates

With the waiting list at a ten-year high, it is vital that increasing demand for transplants is carefully considered by the NHS and government. Our Transplant Care in the UK report, based on 670 survey responses from people affected by kidney disease , provides a unique insight into the patient experience of the kidney transplant journey and an important evidence base for our influencing work. It showed up

----- Start of picture text -----
48
----- End of picture text -----

very clearly the wish for and lack of psychosocial support – we have taken these findings to government to help them to understand why change is needed.

In December we took 22 people affected by kidney disease to Parliament for our Organ Donation Parliamentary Reception, held with NHS Blood and Transplant and hosted by Florence Eshalomi MP, who spoke about her mum’s 11 years on dialysis. Over 60 MPs and peers attended to hear first-hand about the impact of the disease, the transformation a transplant can bring and the challenges of waiting for a suitable organ. The Health Minister Baroness Merron attended and encouraged people to sign the organ donor register and talk to their family about their decision. She spoke highly of Kidney Care UK, saying: “You always see patients as people, not as conditions to be treated, and I commend you for that”. We spoke of the need for earlier identification and treatment of CKD, so fewer people would face kidney failure in the future.

“

CKD seems to be the ‘forgotten’ disease and hopefully by us engaging with the MPs in attendance we brought the message about the importance of organ donation a lot of publicity. My transplant has enabled me to have a life and see my children and amazing grandchildren growing up and have the ability to work and do all the normal everyday things that people take for granted.

Lesley Cole, who attended our reception in Parliament in December 2024

Our Bloody Amazing Kidneys

The autumn of 2024 saw us launch our first ever national awareness campaign, our Bloody Amazing Kidneys campaign. This focused on the amazing job our kidneys do to filter our blood and keep all our organs working but also shared the vital message that you can lose up to 90% of your kidney function without realising.

The aim of the campaign was to use social and digital tools and channels to raise awareness of CKD amongst at risk groups in the UK to improve rates of early identification and diagnosis. The campaign encouraged people to take our online health checker and see if they were at increased risk of developing chronic kidney disease, and also provided information and advice to support them to approach their GP. We also had a small number of posters displayed in shopping centre and service station washrooms as well as some adverts at bus stops and in Candis magazine, and provided all our partner organisations with posters they could display at their offices.

In 2024 we secured more than 300 pieces of media coverage on the campaign, and the posters were scanned over 1,500 times. We also secured a slot in the NHS Primary Care Bulletin which is sent to over 25,000 healthcare professionals and this resulted in more than 100 medical practices sharing the campaign on social media and with their patients.

Our target was to achieve 10,000 completions of our Kidney Health Checker within the first month of the campaign. We hit that target within a week; after the first month 110,000 people had completed the Checker with around 50% identified a being at increased risk. By the end of 2024, 118,935 people had completed the Checker.

By the end of 2024 118,935 people had completed the Kidney Health Checker

----- Start of picture text -----
50
----- End of picture text -----

The campaign has garnered interest across the world, with ongoing discussions with our charity counterparts in Australia, New Zealand, Turkey and Spain taking place. Closer to home, the initial response to the campaign has led us to have conversations with various Kidney Networks and Commissioning Boards in the NHS and we’re excited about the doors this may open in terms of reaching more people who may be at risk of kidney disease and encouraging them to learn more, check their risk and if appropriate get tested to ensure an early diagnosis.

----- Start of picture text -----
51
----- End of picture text -----

Our patient advisory group (PAG)

Established over 10 years ago, and currently with 17 committed patients, this group has grown over the last two years, attracting an increasingly diverse representation of patients across the UK. The PAG meet virtually, up to four times per year, with one in-person meeting. Over the last 12 months they have specifically supported the Charity with:

Our PAG members are often invited to represent the Charity outside of meetings which might include providing patient representation to NICE (National Institute for Health and Care Excellence), attending specific Kidney Care UK events, focus groups for patient information or national conferences, and to support collaborative quality improvement work in the NHS.

PAG is now

10 years old and has 17 members, growing 40% in the last two years

“ Thank you for the opportunity and allowing me to be part of making a real change. It was great to hear the views of other kidney warriors and being able to relate to the issues they face. I’m looking forward to the next meeting and what it holds.

Harkaran, PAG member

----- Start of picture text -----
52
----- End of picture text -----

Raising standards and increasing patient involvement

The Kidney Patient Involvement Network (KPIN) was launched with Kidney Care UK in 2019, to increase the impact of the patient and carer voice and to establish a network to share good practice, offer peer support, and provide training and support to empower more patient leaders. KPIN continues to grow and is the ‘go to’ network for those in the kidney community seeking wider patient representation within their projects, committees, research or service re-design.

With over 300 members (patients, carers and professionals), supported by two trained KPIN facilitators , KPIN continues to grow, develop and flourish. Feedback from professionals and patients involved highlights that KPIN provides a quick and excellent service and offers well trained and supported patient involvement.

Over the last 12 months KPIN facilitators have focused on supporting the clinical networks embedding the patient voice, identifying patients, offering peer support and training to increase patient involvement locally.

----- Start of picture text -----
53
----- End of picture text -----

Managing our charity as effectively and efficiently as possible

Ensuring infrastructure can support our accelerated growth

With the accelerated growth of the Charity in 2024, our IT provision has been vital in ensuring our workforce are able to do their jobs and support more people with kidney disease than ever before. With most staff working on a hybrid working pattern, and many of our patient support services teams working entirely remotely, we need to ensure our IT platforms are stable, have integrity and are secure. Our HR function has also adapted to accommodate the growth of the Charity, and the range of working models across office based, hybrid and fully remote working patterns.

Data and IT support

The planning for the launch of our new database system in 2025 dominated a huge amount of our time in 2024. This is a substantial programme of work and underpins much of our new approach to efficient and digitally supported processes. The implementation phase commenced in September and will run through to March 2025.

We renewed our Cyber Essentials accreditation in 2024, giving reassurance to those sharing information with us that we have the appropriate systems in place to keep their data safe. In January 2024 we updated our device protection by upgrading our antivirus and web defence protection; this not only enhances our defences but will enable us to meet the new requirements for cyber insurance when we complete our annual renewal. In order to maintain the security of our systems, external penetration testing was completed by Cyber Armed Security.

Looking after our people

We welcomed 48 new team members across various departments, taking our headcount from 75 at the start of the year to 110 at the end of the year, an increase of 47%. To make the induction process as smooth as possible in this period of growth, we also implemented a new streamlined onboarding program, ensuring new members of staff are able to hit the ground running and are given all the tools they need to be able to do the best job they can from their very first day.

We’ve encouraged our staff to take advantage of apprentice qualification funding and have several staff signed up to coaching and management qualifications. This not only benefits the Charity, it’s also a fantastic opportunity for our staff to benefit from extensive training to help develop their professional career. In 2024 we also embedded our new staff benefits scheme, which includes mental health support, financial advice, wellness activities. We also offer an enhanced employer pension contributions of 8%,

----- Start of picture text -----
54
----- End of picture text -----

flexible working opportunities, retail discounts and a health cash back plan giving staff access to cash following expenditures on dental, optical, physiotherapy and scans such as MRI scans.

Our staff survey in April gave us some clear guidance on what the team at Kidney Care UK view as the most important areas for us to focus on. Despite the challenges that come with growth we were pleased that we actually increased our Staff Engagement Index score from 82% in 2023 to 85% in 2024. However, we are determined not to rest on our laurels and established a new National Staff Engagement Group, made up of staff from all levels and departments, to work with us to build action plans to improve our ways of working on the things that matter most to our people.

Kidney Care UK had 75 members of staff at the beginning of 2024, growing to 110 by the end of the year: growth of 47%

“

I would recommend Kidney Care UK as a place to work, and I feel that the Charity values their employees. I am proud to be part of the Kidney Care UK team; the passion and commitment from everyone is inspiring. Kidney Care UK member of staff*

Fundraising

Inspiring more people to donate to the Charity so we can support more people affected by kidney disease

2024 was a record-breaking year for the Charity’s income generation with £1 million more being raised through donations and legacies, grants, corporate partnerships and trade in 2024 than in 2023 – an increase of 43%. We receive no government funding and therefore rely on support from our kind and generous supporters to enable us to provide patients with the support they want.

Fundraising income 2024

----- Start of picture text -----
56
----- End of picture text -----

Fundraising income growth In 2023 In 2024 £2.340.889 £3.350.776 fundraising incomegenerated fundraising incomegenerated 2023 2024 Donatkjns from Indlvlduals £181.257 Donatlons In memory 01.220 Logw in¢om• 657 £226A40 Corporate fundrnising ,210.189 Challwge wents £610,233 Commyn•tyfufidrai$ing £202J08 Othèrtradlnglneomo 18a £4SS10 57

Fundraising

We believe in working together with others to ensure people with kidney disease can benefit, this is particularly true with our work with partner organisations through our corporate partnerships. The team secured a record income of £1,210,189 from more than 30 partners. We won our first partnership award with Anglian Water at the Collaboration Network Awards 2024 and companies have built new teams, and new tariffs (including the Anglian Water medical tariff being introduced in April 2025 which is a first in the industry) due to working collaboratively in partnership with us to better serve their customers. This represents tangible change for the kidney community above and beyond financial contributions.

From the Kiltwalk in Scotland to the Cardiff Half Marathon and treks across the South Downs, people across the country have embraced their personal challenges to support us. Record-breaking Hannah and Ede cycled from Land’s End to John O’Groats on tandem bikes, while 90-year-old Trevor raised over £1,500 by cycling 340 miles on his exercise bike. These efforts exemplify the passion and determination of our supporters, driving our success this year.

Our second annual Dog Walking challenge was a huge success, with participants and their four-legged friends walking 32.5 miles over October, raising £15,000. Across 2024, 600 people (and 142 dogs!) took part in various events, raising over £600,000 (an increase of 29% on the year before). One particular standout was the London Marathon 2024, which generated an impressive income of over £242,000.

In 2024 we raised £3,350,776

Thank you - we can’t do what we do without you!

----- Start of picture text -----
58
----- End of picture text -----

The Legenderry Motor Show is a fun family day out and, since 2022, has raised almost £34,000 to support people across Northern Ireland living with kidney disease. “

Kidney Care UK has been proud to be the chosen charity for Legenderry Motor Show for three consecutive years and has built a strong and lasting relationship with the organisers who put their heart and soul into this motoring spectacle.

----- Start of picture text -----
59
----- End of picture text -----

Fundraising

There was an increase of 36% in the number of individual giving donors

Our largest legacy left in 2024 was for £150,000

£101,220 was donated in memory of a loved one

£769,620 was left to the Charity in gifts in Wills

----- Start of picture text -----
60
----- End of picture text -----

£1,210,189 was raised from more than 30 corporate partners

We won our first partnership award with Anglian Water at the Collaboration Network Awards

Our Community Fundraising team raised £202,308, a 39% increase on 2023

More than 600 people (and 142 dogs) took part in a walk, run, cycle or adrenaline fueled activity in 2024, raising more than £600,000

Our London Marathon team raised £242,000

We secured £226,440 through Trusts and Foundations, an increase of 18% compared to 2023

61

Looking ahead to 2025

Our aims and goals

----- Start of picture text -----
62
----- End of picture text -----

“ Our dad was receiving renal care and battled for seven years, he’s no longer suffering with a disease that couldn’t be cured. As a family, we are devastated. We want our donation to help another family on their final journey with their loved ones. Writing this gives me a great sense of pride and happiness.

Donation in memory of a father, grandfather and husband

63

Our financial statements

Financial review of the year

The Charity has experienced its largest year of growth in 2024, with staff numbers increasing to 110 from 75 last year, the vast majority of this growth is in the Advocacy service funded through the Gas Distribution Networks for our Safe and Warm Programme. The Charity has considerably improved and expanded its services for patients and beneficiaries, supported by growth and diversification in our income streams. Our total income for the year increased by 35% to £4,123,556 (2023: £3,052,202), while total expenditure increased by 24% to £6,713,589 (2023: £5,429,930). The Charity benefitted from net gains in investments of £2,144,359 (2023: net gain £1,211,629) as a result of an upturn in investment markets throughout the year. Overall, the net reduction in the Charity’s funds totalled £445,674 (2023: a reduction of £1,166,099).

Income generated increased across a number of income streams, with corporate and event income performing particularly well, whilst we saw a small reduction in income from merchandise sales. Income generated after excluding investment and legacy income increased by 38% to £2,581,156 (2023: £1,861,784), this figure includes £941,285 (2023: £178,157) income from charitable activities and merchandise sales of £47,954 (2023: £55,122). This uplift reflects our strategic objective to support more patients and broaden our income streams. Notable funded projects include the Advocacy & Patient Services expansion (Safe and Warm; funded by our Gas Distribution Network Partners: Cadent, SGN, Wales and West Utilities and Northern Gas Networks) and the Money and Energy Service (funded by the British Gas Energy Trust).

Overall, our charitable activities expenditure increased by 26% in 2024, to £5,664,702 compared to £4,503,936 in 2023. We continued to experience an increase in the need for direct/one-to-one patient services, such as advocacy, counselling and direct patient grants. This is understandable in the wake of the cost-of-living crisis and the expansion of our service reach and awareness. This is in line with our strategy to improve the way kidney patients are cared for across the UK with access to the highest quality holistic care. We also continued to ensure that kidney patients had access to the most accurate, up to date patient information, in hospitals and online.

We continued to invest in our fundraising capability to sustain and advance our fundraised income in the future. Again, this is in line with our strategic aim to inspire more people to support our work, grow income and develop a mature fundraising portfolio, so we can do more to support our beneficiaries. We have seen positive results from our investment, and income has risen significantly, especially non-legacy income which performed particularly well. Expenditure on raising voluntary income increased by 21% to £927,384 (2023: £769,179) reflecting the ongoing expansion of our fundraising capability.

----- Start of picture text -----
64
----- End of picture text -----

As of 31 December 2024, our funds totalled £27,081,772 (2023: £27,527,446), of which £26,688,763 (2023: £27,131,956) is unrestricted. Restricted funds totalled £297,316 (2023: £305,303) and endowment funds £95,693 (2023: £90,187). Of the unrestricted amount, £26,200,000 (this includes tangible and intangible fixed assets with a net book value of £473,086) is set aside as a designated fund to deliver our grant giving programmes in perpetuity; the balance is free reserves which were £488,763 (2023: £431,956). The Trustees agreed that a transfer of £500,000 should be made from the designated fund to the general fund. The transfer was made to off-set the impact of the deficit; the Trustees believe that this is an adequate level required to generate sufficient income to cover the regularly occurring grants and running costs of the Charity.

The Trustees have an aspirational designated fund reserve policy of £30,000,000. The Trustees acknowledge that the current balance of £26,200,000 is below the aspirational target and that this is in part due to the fluctuation in the investments and as a result of the ongoing investment in the Charity’s growth. The Trustees are satisfied that £30,000,000 is appropriate and attainable. The Trustees are content that current reserves levels are sufficient.

Investment policy and performance

At the end of the year under review, Cazenove Capital Management and CCLA Investment Management Limited (CCLA) managed the Charity’s dual investment portfolio split approximately 50%: 50%. The whole of the small Endowment Fund is also managed by CCLA. The funds are split with the CCLA COIF fund operating an active fund managed approach and Cazenove a passive fund solution to diversify the Charity’s investment risk profile. The Investment Managers have full discretionary powers within certain restrictions and limitations, as delegated by the Trustees, and they report to the Finance and Investment Committee on a regular basis. The Finance and Investment Committee and the Trustees continue to be supported by the advice of Enhance Group (UK) Limited, based in Jersey.

During the year, on behalf of the Trustees, the Finance and Investment Committee (the Committee) undertook a competitive tender of the investment portfolio and managers, with the assistance from the Charity’s investment advisors. The Committee carried out the review during May and June 2024 and put their recommendations to the Board in June 2024. The tender was underpinned by the following evaluation criteria: Performance, Process, People, Planet and Price. After concluding the tender, the Trustees agreed that the Charity should retain Cazenove Capital Management and replace Evelyn Partners Investment Management LLP with CCLA Investment Management Limited, investing in their COIF Charities Investment Fund (COIF Fund). The removal, appointment and onboarding process started in July 2024 and was fully complete by November 2024. The funds held by Evelyn Partners were managed as a segregated portfolio, while the COIF Fund is a pooled fund, therefore, to transition between investment managers, holdings in individual investments were disposed of, converted to cash

----- Start of picture text -----
65
----- End of picture text -----

and used to purchase units in the COIF Fund. Some of the investments were transferred “in specie” and then converted into COIF units. For this reason, there are material disposals and additions showing in the investment note (note 20) of the accounts.

Stock market conditions were fair throughout the year with the cooling of inflation and easing of interest rates. Equity markets performed well resulting in a realised and unrealised increase of circa 8% of funds under management, amounting to a £2,144,359 gain (2023: £1,211,629 gain). The Trustees appreciate that global markets are likely to remain volatile throughout 2025.

The investment objective is to achieve a long-term total return as a result of growth in capital and income derived from a diversified portfolio of investment assets with a moderate degree of risk. As of 31 December 2024, the Charity’s investments were 75% in equities, 11% in fixed interest, 11% in property and alternatives and 3% in cash.

Kidney Care UK’s investment policy stipulates there should be no direct exposure to tobacco stocks.

Reserves policy

The Trustees have reviewed the Charity’s needs for reserves in line with the guidance issued by the Charity Commission. For the foreseeable future, the Trustees anticipate that there will be significant growth in the need for support of renal patients. This is driven by changing demographics and the increasing incidence of renal failure as a proportion of the population in the UK, along with government spending challenges for the NHS.

For the foreseeable future, within the parameters of its current policies, the Charity expects to be able to meet the needs for financial support of patients and their families. The Charity expects to be able to sustain its support for, professional, clinical and social carers, the development of services and facilities, and the provision of equipment for the better treatment of kidney patients and their families, and research into the effectiveness of those services and provisions.

Kidney Care UK readily re-deploys elements of its investments to fund posts, projects or research or for cash flow purposes. The Charity relies on investment income and capital appreciation to fund day-today expenditure in support of its primary charitable objects and continues to invest in its growth and transformation i.e. improving the quality of life of kidney patients. The Charity could not deliver the help needed to support its beneficiaries without its investment income and Kidney Care UK is therefore not at liberty to deploy invested funds elsewhere without potentially incurring a penalty to the future delivery of its primary objective. The Charity’s free reserves are £488,763 as defined in the SORP, which would cover about one month of expenditure. The Charity’s investments will remain an essential source of income to

----- Start of picture text -----
66
----- End of picture text -----

meet our charitable objects and can be drawn down as needed.

The Charity has set aside a core designated invested reserve fund, the income and capital appreciation of which, together with voluntary donations and income arising from other activities, will for the foreseeable future provide for the administration of the Charity, the needs of our “Objects”, and the depreciation of the purchasing power of resources by inflation. In addition, the Charity will seek to retain sufficient surplus resources to mitigate against the inherent volatility of holding investments. The reserves policy and level of the core investment funding is reviewed annually by the Board. Resources in excess of the Designated Reserve are retained as a General Reserve, which the Trustees will seek to apply appropriately over the short term.

Going concern

The economic uncertainty caused by the changes to US trade tariffs, the ongoing war in Ukraine and the continued uncertainty in the Middle East does pose risk to the short-term value of investments in 2025. However, our approach remains to take a long-term view of our investments and we remain confident that the steps and processes we have put in place will allow us to ride out the continued volatility and support a sustainable growth plan. As a result, our Trustees have reviewed our financial position and plans along with our risk management in light of the current environment and have a reasonable expectation that the Charity has adequate resources to continue in operational existence for the foreseeable future. For this reason, they continue to adopt the going concern basis in preparing the financial statements. Further details regarding the adoption of the going concern basis can be found in the Accounting Policies.

Grant making

Kidney Care UK makes grants to hospitals, to fund innovation and quality improvements in kidney patient care, and to help patients struggling to make ends meet. Both schemes are managed in a formal and consistent process, according to a clear and comprehensive set of guidelines. Hospital grant applications are formally peer reviewed by the Grants Committee, containing experts in their field, and scored against clearly defined and published guidelines. The Committee makes a recommendation for funding to the Board for their review and approval. In all instances where there is a conflict of interest, the Committee Member is excluded from any discussion and decision.

----- Start of picture text -----
67
----- End of picture text -----

Our structure, governance and management

Structure

Kidney Care UK is a charitable company limited by guarantee, incorporated on 29th September 1975. The company was established under a Memorandum of Association which establishes it objects and powers and is governed under its Articles of Association. The company is registered as a company in England and Wales, registration number 1228114. Kidney Care UK is registered as a charity with the Charity Commission for England and Wales, charity number 270288 and in Scotland with the Office of the Scottish Regulator, registration number SC048198. In the event of the company being wound up members are required to contribute £10.

Trustees

The Board of Trustees is legally responsible for directing our affairs. They are Directors of the company and serve for renewable terms of three years, up to a maximum of nine years. Our articles mandate that the Board should be between 8 and 16 members and the Charity considers that 12 is the optimum number of Board members to service the Committees of the Board. As at the date of signing the Charity had a total of 14 Trustees. The Board have a wide range of skills, knowledge and experience including clinical and professional. We monitor the mix of skills and length of service to ensure that we maintain a good balance and recruit new Trustees in a timely fashion. The Trustees who served during the year are detailed on pages 73 to 74.

The Board appoints all new Trustees on the advice of a Nominations Committee, and we recruit Trustees through a process of advertisement, application and interviews, and on a selection criterion that ensures a broad range of relevant skills, experience and diversity is maintained. We offer a tailored induction programme and provide further updates and training as needed. The Board makeup is reviewed annually at Board level.

The Board of Kidney Care UK are committed to good governance and recognise the importance of continued development. Following a full external governance review in 2019, the Charity conducts an annual Board self-evaluation survey, which along with any changes to the Governance Code, results in an annual Board Governance Development Plan, ensuring a culture of ongoing review and improvement. Changes to the Charity Commission Governance Code, published in December 2020, were reviewed by the Governance, Strategy & Risk Committee in 2021 and actions as a result were reflected in the annual plan to ensure continued compliance both in letter and spirit.

----- Start of picture text -----
68
----- End of picture text -----

Decision making

The Board of Trustees meets four times a year to regularly review Kidney Care UK’s general policies, strategy, budget and performance. The Board delegates the day-to-day management of the Charity to the Chief Executive and Senior Management Team. Specific responsibilities are delegated to four Board Committees, under terms of reference agreed by the Board and which report back to the Board on a regular basis. All Committees are advisory and decision-making authority is retained by the full Board.

Key management and staff remuneration

The Senior Management Team is responsible for the day-to-day running of the Charity and comprises the Chief Executive, and the Directors of Policy, Fundraising, Marketing & Communications, Finance, and Patient Support.

----- Start of picture text -----
69
----- End of picture text -----

The pay of the Charity’s Chief Executive is reviewed annually by the Board, based on market rates and benchmarks, personal performance and scope and complexity of the role.

Volunteers

The Board and Senior Management Team are supported and advised on issues affecting patients by our Patient Advisory Group (PAG), made up of around 20 kidney patients and carers, many of whom are officers of local kidney patient associations. In addition, the Charity recruits peer supporter volunteers to deliver its peer support service, who are managed by the Peer Support and Volunteer Manager. As with Trustees, volunteers receive no remuneration, only expenses.

Our risk management

The Board of Trustees has overall responsibility for risk management at Kidney Care UK. This includes setting the risk appetite for the Charity (formal risk appetites are codified in the Charity’s risk register), ensuring that there are reasonable procedures in place for the prevention and detection of major risks and ensuring that risk procedures are reviewed when issues arise. The Board formally review the Risk Policy and Register twice a year. The Board considers risks to be anything that can adversely affect our ability to achieve our objectives for people affected by kidney disease, sustain our operations, maintain our reputation or meet legal and regulatory requirements. The Charity maintains a suite of core organisational policies, covering all aspects of its work and management, which are subject to a formal, regular review cycle and supported by our committee structure.

The Board are supported by the Audit and Risk Committee (A&R) which plays a key role in overseeing management of our principal risks and provide assurance to the Board that we have adequate risk management systems and mitigating actions in place. The Committee undertakes twice yearly risk reviews and the Senior Management Team monthly meetings, chaired by the Chief Executive, oversee a comprehensive annual planning and budgeting process, performance monitoring through key performance indicators and a regular review and monitor of key strategic and operational risks. The Board consider this an effective approach to evaluate significant risks to the Charity, establish effective controls and determine necessary and prompt action.

----- Start of picture text -----
70
----- End of picture text -----

Principal risks identified and controls

Data and information security

We have a dedicated Data and IT Manager who ensures that policies and procedures are in place to protect staff, supporter and beneficiaries’ personal data, oversee regular (annual) staff training on data protection and cyber security, and ensure we comply with the highest standards stipulated in guidelines and regulations. The Charity regularly reviews its data protection and privacy policies and conducts security audits with independent third-party organisations to ensure its cyber security is robust. In 2024, as a result of the increased threat from cyber-attacks we conduct annual penetration testing to ensure that our security systems and protocols were sufficient and were pleased that only low risks were identified. In 2024 we were also pleased to retain our Cyber Essentials accreditation and we continue to ensure we maintain the Charity’s high levels of security.

Service quality in patient care

Kidney Care UK’s key risk is that patients receiving support from the Charity suffer harm or ineffective care as a result of our actions. The Charity has a robust safeguarding policy, including a Designated Safeguarding Officer and Deputy Safeguarding Officer, the Patient Services Team meets quarterly and receives regular high-quality training on areas such as safeguarding and Equality and Diversity, and the Charity has a published complaints policy and log, which is regularly reviewed by the SMT and the Board, along with patient and carer feedback and incident reporting. Our counselling service is staffed by fully qualified and accredited counsellors who adhere to the BACP guidelines and regulatory framework. We continue to strengthen our Safeguarding governance framework and have a named Trustee to act as the Board Safeguarding Lead.

Investment performance

Kidney Care UK’s investments are managed on a total return basis. The Trustees consider variability of returns on the Charity’s investment portfolio and a significant drop in the value of the portfolio to constitute the Charity’s principal financial risk. A 10% drop in the value of the portfolio triggers the discretionary investment managers and the finance advisors to enter immediate discussions with the Finance and Investment Committee. Investment managers and our financial advisors produce regular reports (quarterly) to the Finance and Investment Committee, which in turn reports quarterly to the Board of Trustees. The investment portfolio is divided between two investment managers to reduce the Charity’s investment risk profile, and the Board have agreed a medium risk appetite. In 2022, the Trustees agreed to strengthen our alignment with ESG investment principles, but through a progressive approach

----- Start of picture text -----
71
----- End of picture text -----

that does not alter the primary objective of protecting and responsible management of the Charity’s current capital assets. The Finance and Investment Committee are charged with taking this programme of work forward.

Fundraised income

Kidney Care UK’s strategic growth is dependent on achieving fundraising targets. The organisation has developed a fundraising strategy that looks to realise a diverse range of funding opportunities and a mature, balanced fundraising programme. We have strengthened the knowledge and skills in the fundraising team to enable delivery of our strategy. Monitoring of actual income to budget and forecast is achieved by a monthly review of reports by senior management and with oversight by the Finance and Investment Committee. Kidney Care UK regularly reviews its fundraising procedures to ensure compliance with the Fundraising Code of Practice. There were no identified failures in compliance with this Code, nor any complaints received by the Charity in respect of fundraising in the year. Kidney Care UK protects vulnerable people and other members of the public by ensuring that its fundraising activities are not considered to be an unreasonable intrusion on a person’s privacy or an unreasonably persistent approach and do not place undue pressure on a person to give money.

Loss of key staff

In common with most small and medium sized charities, Kidney Care UK is at risk of performance challenges through the loss of key staff. The Charity’s transformation in recent years has allowed us to reduce this risk by developing greater sustainability through increasing staffing for key roles. Having strengthened the Senior Management Team in 2022, we have continued (funds permitting) to increase staff numbers in areas where the pressure of increasing work volumes and threat of “single points of failure” or lack of segregation of duties, increase our risks. We introduced our first Staff Engagement Survey in 2023 and were pleased to achieve an 82% Staff Engagement Index score, we undertook this survey in 2024 and were delighted to achieve an 85% Staff Engagement Index Score as well as reviewing our staff benefits package and launching an enhanced package in January 2024.

----- Start of picture text -----
72
----- End of picture text -----

Reference and administrative details of the Charity, its Trustees and advisors

Trustees

Graham Lipkin MB ChB, BSc, MD, FRCP (UK) (Chair) Amar Radia ACA, MA (Cantab) Angela Griffiths (Chair of Staffing and Remuneration Committee) Caroline Price Grainne Walsh MSc, BSc, DipHe(Nurs), RSCN (Chair of Grants Committee) John Henry Brown MD, FRCP, FRCPI Lewis Temple Madeleine Warren Michael Zelouf Robert Lant (Chair of Finance and Investment Committee) Sally Hulton MD, FRCPCH, MBBCh Sarah Hillary (Chair of Audit and Risk Committee) Shivani Sharma CPsychol William Richard Caldwell

Company Registered Number

1228114 (England and Wales)

Charity Registered Number

270288 (England and Wales) SC048198 (Scotland)

Registered Office and Operating Office

3 The Windmills, St Mary’s Close, Turk Street, Alton, Hampshire, GU34 1EF

Chief Executive

Paul Bristow

----- Start of picture text -----
73
----- End of picture text -----

Senior Management Team

Paul Bristow

Fiona Loud

Laurie Cuthbert Sarah Oakley Charlotte Donnelly

Company Secretary

Southern Secretarial Services Ltd, Wey Court West, Union Road, Farnham, Surrey, GU9 7PT

Auditors

Kreston Reeves, 9 Donnington Park, 85 Birdham Road, Chichester, PO29 7AJ

Bankers

Lloyds TSB PLC, 75 Castle Street, Farnham, Surrey, GU9 7LT

Investment Managers

Cazenove Capital Management, 12 Moorgate, London EC2R 6DA CCLA Investment Management Limited, One Angel Lane, London, EC4R 3AB

Investment Advisers

Enhance Group Limited, 3rd Floor, 29/31 Esplanade, St Helier, Jersey JE2 3QA

----- Start of picture text -----
74
----- End of picture text -----

Statement of Trustees’ responsibilities For the year ended 31 December 2024

The Trustees (who are also the directors of the Charity for the purposes of company law) are responsible for preparing the Trustees’ report including the Strategic report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial year. Under company law, the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Charity and of its incoming resources and application of resources, including its income and expenditure, for that period. In preparing these financial statements, the Trustees are required to:

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the Charity’s transactions and disclose with reasonable accuracy at any time the financial position of the Charity and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Disclosure of information to auditors

Each of the persons who are Trustees at the time when this Trustees’ report is approved has confirmed that so far as that Trustee is aware, there is no relevant audit information of which the Charity’s auditors are unaware, and that Trustee has taken all the steps that ought to have been taken as a Trustee in order to be aware of any relevant audit information and to establish that the Charity’s auditors are aware of that information.

In approving the Trustees’ Annual Report, we also approve the Strategic Report included therein, in our capacity as Company Directors.

----- Start of picture text -----
75
----- End of picture text -----

Approved and authorised for issue by the Trustees and signed on their behalf by:

................................................

Dr Graham Lipkin MB ChB, BSc, MD, FRCP (UK)

Chair of Trustees Date: 25 June 2025

----- Start of picture text -----
76
----- End of picture text -----

Auditors’ report

THE BRITISH KIDNEY PATIENT ASSOCIATION T/A KIDNEY CARE UK

(A company limited by guarantee)

INDEPENDENT AUDITORS’ REPORT TO THE MEMBERS OF THE BRITISH KIDNEY PATIENT ASSOCIATION T/A KIDNEY CARE UK

Opinion

We have audited the financial statements of The British Kidney Patient Association t/a Kidney Care UK (the ‘Charity’) for the year ended 31 December 2024 which comprise the Statement of financial activities, the Balance sheet, the Statement of cash flows and the related notes, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland’ (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors’ responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the United Kingdom, including the Financial Reporting Council’s Et ical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

----- Start of picture text -----
77
----- End of picture text -----

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the Trustees’ use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company’s ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the Trustees with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the Annual report other than the financial statements and our Auditors’ report thereon. The Trustees are responsible for the other information contained within the Annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinion on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

• the information given in the Trustees’ report including the Strategic report for the financial year for which the financial statements are prepared is consistent with the financial statements.

• the Trustees’ report and the Strategic report have been prepared in accordance with applicable legal requirements.

----- Start of picture text -----
78
----- End of picture text -----

Matters on which we are required to report by exception

In the light of our knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the Trustees’ report including the Strategic report.

We have nothing to report in respect of the following matters in relation to which Companies Act 2006 and the Charities Accounts (Scotland) Regulations 2006 (as amended) require us to report to you if, in our opinion:

Responsibilities of Trustees

As explained more fully in the Trustees’ responsibilities statement, the Trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Trustees are responsible for assessing the charitable company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Auditors’ responsibilities for the audit of the financial statements

We have been appointed as auditor under section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and under the Companies Act 2006 and report in accordance with the Act and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditors’ report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it

----- Start of picture text -----
79
----- End of picture text -----

exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

Capability of the audit in detecting irregularities, including fraud

The objectives of our audit are to identify and assess the risks of material misstatement of the financial statements due to fraud or error; to obtain sufficient appropriate audit evidence regarding the assessed risks of material misstatement due to fraud or error; and to respond appropriately to those risks.

Based on our understanding of the Charity and industry, and through discussion with the directors and other management (as required by auditing standards), we identified that the principal risks of noncompliance with laws and regulations related to health and safety, anti-bribery and employment law. We considered the extent to which non-compliance might have a material effect on the financial statements. We also considered those laws and regulations that have a direct impact on the preparation of the financial statements such as the Companies Act 2006, Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland. We communicated identified laws and regulations throughout our team and remained alert to any indications of non-compliance throughout the audit. We evaluated management’s incentives and opportunities for fraudulent manipulation of the financial statements (including the risk of override of controls), and determined that the principal risks were related to: posting inappropriate journal entries to increase income or reduce expenditure, management bias in accounting estimates and judgemental areas of the financial statements such as accounting treatment of grants awarded not yet claimed and accounting for legacies receivable. Audit procedures performed by the engagement team included:

----- Start of picture text -----
80
----- End of picture text -----

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

As part of an audit in accordance with ISAs (UK), we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

----- Start of picture text -----
81
----- End of picture text -----

in our Auditors’ report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our Auditors’ report. However, future events or conditions may cause the charitable company to cease to continue as a going concern.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Use of our report

This report is made solely to the charitable company’s members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006, and to the charitable company’s trustees, as a body, in accordance with regulation 10 of the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the charitable company’s members and Trustees those matters we are required to state to them in an Auditors’ report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and its members, as a body, for our audit work, for this report, or for the opinions we have formed.

................................................

Lucy Hammond BSc FCA (Senior Statutory Auditor)

for and on behalf of

Kreston Reeves LLP

Chartered Accountants Chichester

Date: 7 July 2025

----- Start of picture text -----
82
----- End of picture text -----

THE BRITISH KIDNEY PATIENT ASSOCIATION TIA KIDNEY CARE UK {A company limited by guarantee) STATEMENT OF FINANCIAL ACTIVITIES (INCORPORATING INCOME AND EXPENDITURE ACCOUND FOR THE YEAR ENDED 31 DECEMBER 2024 Endowment funds 2024 Restricted Unrestricted funds funds 2024 2024 Total funds 2024 Total funds 2023 Note Income and endobvments frorn: Donations and legacies Charitable activities Other trading aclivits'es Investments 468.282 941,285 1.891,689 2,359.981 941,285 47,954 772,780 2,107,610 178,157 55,122 711,313 47,￿4 770,074 1,556 2,706 Other income Total Income and endo%Mnents 2,706 1,409,567 2,711,283 4,123,556 3,052,202 Expenditure on: Raising funds Chantable activities 9,10 11 72 3,113 1,391,243 1,045,702 4,270,825 1,048,887 5,664.702 925,994 4,503,936 2,634 Total expendlture 2,706 1,394,356 5,316,527 6,713,589 5,429,930 Net incorne I lexpenditurel beforé net Ilosse51 I gains on inve5tment5 15,211 {2,8OS,2441 {2,$9),033) 12,377,728) Nel Ilossesl I gains on investments 5.606 2,138,853 2,144.369 1,211,629 Net income I lexpenditurel Transfers tEtween funds 5,506 15,211 {466,3911 1445,674) 11,166,099) 24 123,1981 23,198 Net movement in funds 5,506 17,9871 1443,1931 1445,674) 11,166.0991 Reconciliation of funds.. Total funds brought forward .187 5,506 305,303 17,9871 27,131,956 {443,1931 27,527,446 28,693,545 1445,674) 11,166,099) Nel movement In fuThJs Total funds earrléd forward 95,693 297,316 26,688,763 27,081,772 21,527,446 The Statement of financial activities includes all gains and losses recognised In the year. The notes on pages 87tr) 113 form part of trese financial statements. 83

THE BRITISH KIDNEY PATIENT ASSOCIATION TIA KIDNEY CARE UK (A company limited by guarantee) REGISTERED NUMBER.. 1228114 BALANCE SHEEr AS AT 31 DECEMBER 2W24 2024 2023 Note Fixed assets IntangitAe assets Tangible assets I￿eStMentS 18 72,252 4￿,834 26,391,767 19 20 404,698 27,020,576 26,864,853 27,425,274 Current assets Debtors Cash at bank and in hand 21 1,252,842 426,447 563,845 618,754 1.679.289 1,182,599 Creditors.. amounts falling due within one year 22 11,317,031) 1933,8411 Net current assets 362,258 248,758 Total assets less current liabilities 27,227,111 27,674,032 Creditors.. amounts falling due after more than one year 23 114S,3391 1146,5861 Total net assets 27,081,772 27,527,446 84

THE BRITISH KIDNEY PATIENT ASSOCIATION TIA KIDNEY CARE UK {A company lirnited by guarantee) REGISTERED NUMBER.. 1228114 BALANCE SHEET (CONTINUED) AS AT 31 DECEMBER 2W24 2024 2023 Note Charity funds Endowrnenl furKJs 24 95,693 297,316 26,688,763 90,187 305,303 27,131,956 Restricted funds Unrestricted funds 24 24 Total funds 27,081,772 27,527,446 The Trustees ackno￿edge their resKx)nsibilities for complying wrth the requirements of the Act with respect lo 8ccounting records arKI preparation of finawial statements. The financial staterrEnls were approved and autkKJrised for issue by the Trustees and signed on their Ikhalf ty". Mr Robert Lant Chair of Finance and Investment Committee Dale.. 25 June 2025 The notes on pages 87 to 113 form part of these financial statements. 8S

THE BRITISH KIDNEY PATIENT ASSOCIATION TIA KIDNEY CARE UK (A company Ilmlted by guarantee) STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31 DECEMBER 2W24 2024 2023 Cash flows from operating activities Net cash used In oper8ting adwities {3,630.7001 12,542,156) Cash flows from investing activities 8ank interest Dividend Income 1,181 703,891 771,790 1,556 (109,1111 150,3151 18,531310 7,147,631 115,471,873) 15,499,154) Proceeds from the sale of laryible fixed assets Purchase of fixed assets Net proceeds from sale of InvestrrEnts Purchase of investments Net cash provided by investing activities 3,725,662 2,303,234 Change in cash and cash equivalents in the year 84.962 (238.922) Cash and cash equivalents al the teginning of the year 1,083,425 1,322,347 Cash and cash equivalents at the end of the year 1,178,387 1.083,425 The notes on pages 87 to 113 form part of these fina[￿la1 statements 86

THE BRITISH KIDNEY PATIENT ASSOCIATION TIA KIDNEY CARE UK (A company lirnited by guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024 General information The company is a charitable o)mpany limited ty guarantee, incorwraled in England and Wales. The Iruslees on page 1 are also members of the company. In the event of the company being wound up, the liability in respect of the guarantee is limited lo £10 per memter. The registered office is 3 The WirKJmills, Sl Mary's Close, Turk Street, Alton, GU34 1 EF. Accounting policies 2.1 Basis of preparation of financial statements The financial statements have tEen prepared In accordance with the Charities SORP IFRS 1021 Accounliry and Reporting ty Charities Statement of Recommended Practice applicable lo charities preparing their accounts in accordance with the Financial Rew>rting Stsndard applicable in the UK and Republic of Ireland IFRS 1021 (effective 1 January 20191, the Financial ReEK)rting Standard applicable in the UK arKJ RepubliG of Ireland IFRS 1021 and the Companies AGt 2006. The British Kidney Patient Association Ve Kidney Care UK meets the definition of a public benefit entity under FRS 102. Assets and liabilities are Initially recognised al historical cost or transaction value unless otrewise stated in the relevant accounting Kx)IIGy. 2.2 Going concern The Trustees have a reasonable exFeclation that the charity has adequate resources to continue in operational existence for the foresee8ble future. Thus they continue to adopt the going concern basis in preparing the annual financial stalemenls. The continuing Impact of the cost of living crisis has teen included in charity's forecasting and in the planning of future and the going con￿rn assumption takes this into consideration. 2.3 Income All income is reGognised onGe the Charity has enlrtlement lo the Income, it is probable th8t the income will LE reTrived and tre amount of iwome receivable can be rrEasured reliably The reGognition of Income from legacies is dependent on establishing enb"tlement, the probability of receipt and the 3bility to estimate witr sufficient accuracy the amount re￿1Vable. Evidence of enlillement to a legacy exists when the Charity has sufficient evidence th8t a gift has been lefl lo them (through knowledge of the eXiSte￿e of a valid will and the death of the tEnefactorl and the executor Is s8tisfied that the propetty in question will not LE required to S8tisfy claims In the estate. Receipt of a legacy must recogni*d when It is prothable that il will ￿ received and the fair value of the amount receivable, which will ￿nerallY te tre expected cash amount to tE distritrArted lo the Charty, can be reliably measured. Grants are Included In the Statement of financial activities on a receivable basis. The balance of income received for specific purposes ￿t not exFended during the period is skx)wn In the relevant funds on the Balance sheet. Where Income Is received in advan￿ of entitlement of re￿ipt, its recognition is deferred and Included in creditors as deferred Iwome. Where entitlement occurs tefore income Is received, the Imome is accrued. Income lax recoveratAe in relation lo investment income is reccNJnised at the lime the investment income is receivable. 87

THE BRITISH KIDNEY PATIENT ASSOCIATION TIA KIDNEY CARE UK (A cornpany limited by guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 21r24 Accounting policies Icontinuedl 2.4 Expenditure Expenditure is recognised once there is a legal or constructive otAigation to transfer economic tenefit lo a third paty, it is probable that a transfer of economic ￿nefItS will be required in selllemenl and the amount of the obligation can rrÈasured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attriblrtable lo a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not allributable to a single activity are apportioned t£￿een those activities on a basis consislenl with the use of resources. Central staff costs are allocated on the basis of time s￿nt, and depreciation charges allocated on the portion of the asset's we. Expenditure on raising funds includes all expenditure incurred by the Charity lo raise funds for its charitable purwses and includes costs of all fundraising activities events and non-charilable trading Expenditure on charitable activities is incurred on directly undertaking the acb'vilies which further the Charity's objectives, as well as any associated support ￿$ts Grants payable are charged in the year when the offer is made except in those cases where the offer is conditional, such grants being recognised as expenditure when the conditions attaching are fulfilled Grants offered subject lo conditions which have not tEen rnel at the year erKJ are noted as a commitment, but not accrued as exFEndilure 2.5 Interest receivable Interest on funds held on dewsit is included when receivable and the amount can LE rnea5ured reliably by the Charity, this Is norrnally notification of the interest paid or payable by the inslilubon with whom the funds are de￿sIted 2.6 Takition The Charity is considered to pass the lesls set out in Paragraph 1 Schedule 6 of the FIrnan￿ Act 2010 and therefore Il meets the definition of a charitable company for UK corporation tax purrx)ses. Accordingly. the Charity is FK)tentially exempt from taxation In respect of income or capital gains re￿IVed within categories covered by Chapter 3 Part 11 of the CorFX)ralion Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Art 1992, to the extent that such income or gains are applied exclusively to charitable purtx)ses. 2.7 Intangible assets and amortisation Intangible assets Gosting £1,000 or more 8re caprtalised and recognised when future economic I￿ne[lIS are probable, 8nd the cost or value of tre asset can LE measured reliably. Intangible assets 8re Inrtially recognised al cost. After recognition, urKler the cost model, intaruible 8ssels are measured al cost less any accumulated amortisalion and any accumulated Impairment losses. Amortisalion is provided on intangible assets at rates calculated to write off the cost of each asset on a straight-line basis over its exFecled useful life. estimated useful lives are as follows.. Computer sofvare 8 years 88

THE BRITISH KIDNEY PATIENT ASSOCIATION TIA KIDNEY CARE UK (A company lirnited by guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024 Accounting policies (continued) 28 Tangible fixed assets and depreciation Tangible fixed assets costing £1,000 or more are capitalised and reccNJnised when future economic tenefits are probatAe and the cost or value of the asset can measured reliably. Tangible fixed assets are initially recognised al cost. After recognition, urKler the cost m(￿e1, tangible fixed assets are measured al ￿st less accumulated depreciation and any accumulated impairrrEnt losses. All costs incurred to bring a tangible fixed asset into ils intended working condition should induded in the measurement of cost. [￿preCIatIon is charged so as lo allocate the cost of tangible fixed assets less IkEir residual value over their eslimaled useful lives, using the straight-line melkK)d. [￿preCIatIon is provided on the following bases.. Freehold proFerty Fixtures and fittings Office equipment 50 years straight line 10 years slraighl line 3 years straight line 29 Investments Fixed asset investments are a form of financial instrument and are initially recognised at their transaction cost and subsequently measured at fair value al the Balance sheet dale, unless the value cannot be measured reliably in which case il is measured at cost less impairment Investment gair and losses, whether realised or unrealised, are combined and presented as 'GainsllLossesl on investwÈnts' in the Statement of financial activities. 210 Debtors Trade and other debtors are recognised at the settlement amoLJnt after any trade discount offered. Prepayments are valued al the amount prepaid net of any trade discounts due. 211 Cash at bank and In hand Cash at bank and in hand inclLJdes cash and short-term highly liquid investments with a short maturity of three months or less from the date of a(4LJiSition or 0[￿nIng of the deposit or similar account. 89

THE BRITISH KIDNEY PATIENT ASSOCIATION TIA KIDNEY CARE UK (A cornpany limited by guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024 Accounting policies (continued) 2.12 Liabilities and provisions Liabilities are recognised when there is an obligation al the Balance sheet dale as a result of a past event, il is probable that a transfer of economic tenefit will tE required in settlement, and the amount of selllement can tE estimated reliably. Liabilities are recognised al the amount tral the Charty anticipates il will pay lo sellle the debt or tk amount it has received as advanced payments for the goods or *rvices it musl provide. A conlingenl liability is identified and disclosed for those grants resulting from.. a wssible obligation which will only be confirmed ty the occurrence of one or more uncertain future events not wholly within the Iruslees, control.. or a present obligation followir¥J a grant offer where settlerrEnt is either not considered probable, or the amount has not teen communicated In the grant offer and that amount cannot te estimated reliauy. 2.13 Flnanclal Instruments The Charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments Basic financial instruments are inrtially recognised al transaction value and SLJbseqLJently measured al their settlement valLJe with the exception of bank loarts which are SLJbsequendy measured at amrtised c051 u&ng the effective interest metthd. 2.14 Pensions The Charity OFErates a defined contritxrtion pension scheme and the ￿nSIOn charge represents t amounts payable ty the Charity lo the fund in respect of the year 2.15 Fund accounting General funds are unrestricted funds which are availatAe for use al the discretion of the Trustees in furtherance of the general objectives of the Charity and which have not been designated for other purposes Designated funds cornprise unrestricted funds that have been set aside by the Trustees for pgrticular purposes The aim and use of each designated furKJ is set out in the note5 to the financial statements. Restricted funds are furKJs which are lo tE used in accordance with specific reslriclions irnposed by dorK)rs or which have raised by the Chanty for particular pur￿Ses. The costs of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes lo the financial statements. Endowment funds are funds, the incorrE from which, are to Used In accordance with spEcific reslriclions IrnFK>sed by donors The cost of raising and administrating such funds are charged against the SFEcific fund. The aim and use of the endowment fund is sel out In the notes to the financial statements Investment Income, gains and losses are allocated to the appropriate fund. 90

THE BRITISH KIDNEY PATIENT ASSOCIATION TIA KIDNEY CARE UK IA company limited by guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024 Critical accounting estimates and areas of judgment Estimates arKJ judgments are continually evaluated and are based on historical experieme and other factors, including expectations of future events that are tElieved lo be reasonatAe under the circumstances. Critical accounting eslimales and assumptions.. The Charity makes estimates and assumptions concerning the future. The resulting accounting ests'mates and assumptions will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets aThJ lialj'lrties within the next financial year are discussed t￿low. Critical areas of judgment.. Le cies receivable The Charity only recognises legacy income when il is certain to be received and can measured or estimated with sufficient reliability Estimations of legacy income may based on a solicitor5 valuation of an estate and therefore adjustments may need lo be made following actual receiF*s. Therefore some amounts included in the financial stalernents are estirnations. Grants comrnitted The Charity recognises grants committed as a contingent liability once the grant has been approved by the Grants Committee When the conditions of the grant are achieved by all parties, the grant Is recognised as a creditor in the financial statements A ILKJgement is made to determine that all conditions have tEen satisfied. 91

THE BRITISH KIDNEY PATIENT ASSOCIATION TIA KIDNEY CARE UK IA company Ilnlted by guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024 Income from donations and legacies Restricted Unrestricted funds funds 2024 2024 Total funds 2024 Donati0Tr6 Legacies Grants 397,570 70,712 1,176,191 698,908 16,600 1,S73,761 769,620 16,600 Total 2￿24 468,282 1,891,699 2,359,981 Restricted Unrestricted funds funds 2023 2023 Total funds 2023 Donations 383,627 1,244,878 479,105 1,628,505 479,105 Legacies Total 2023 383,627 1,123,983 2,101,610 Income from charitable activities Restricted funds 2024 Tolal funds 2024 Direct patient support 941,285 941,285 Restricted funds 2023 Total funds 2023 Direct patient support 178,157 178,157 92

THE BRITISH KIDNEY PATIENT ASSOCIATION TIA KIDNEY CARE UK IA cornpany limitad by guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024 Income from other trading activities Income from non charitable trading activities Unrestricted funds 2024 Total funds 2024 Non-charitable trading - MercharKlise sales 47,954 47,9S4 Unreslricled funds 2023 Total funds 2023 Non-charitable trading - MercharKlise sales 55,122 55,122 Investment income Endowment Unrestricted funds funds 2024 2024 Totsl funds 2024 Income frorn listed investrnents 2,706 769,084 990 771,790 Bank interest Total 2024 2,706 770,074 772,780 Endowment Unrestricted funds funds 2023 2023 Total funds 2023 IncorrE from listed I￿estmentS Bank interest 2,102 708,030 1,181 710,132 1,181 Total 2023 2,102 709,211 711,313 93

THE BRITISH KIDNEY PATIENT ASSOCIATION TIA KIDNEY CARE UK IA company limited by guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024 other incoming resources Unrestricted funds 2024 Total funds 2024 Total funds 2023 Other iwome 1,556 1,SS6 Investment management costs Endowment Unrestricted funds funds 2024 2024 Total funds 2024 Investment management fees 72 121,503 ErKJowmenl Unreslricled funds funds 2023 2023 Total funds 2023 Investment management fees 72 156,743 156,815 10. Expenditure on raising funds Costs of raising voluntary income Restricted Unrestricted funds funds 2024 2024 Total funds 2024 Costs of raising voluntary income 3,113 924,271 927,384 94

THE BRITISH KIDNEY PATIENT ASSOCIATION TIA KIDNEY CARE UK IA company limited by guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024 10. Expenditure on raising funds {continued) Costs of raising voluntary income Icontinuedl Unreslricled funds 2023 Total funds 2023 Costs of raising voluntary income 769,179 769,179 11. Analysis of expenditure on charitable activitiés Surnmary by fund type EndOwn￿nt funds 2024 Restricted Unrestricted funds funds 2024 2024 Total 2024 Direct patient support 2,634 1,391,243 4,270,825 5,664.702 Endowment funds 2023 Restricted Unreslricled funds funds 2023 2023 Total 2023 Direct patient support 2,030 410,095 4,091,811 4,503,936 12. Analysis of expenditure by activities Activities undèrtaken directly 2024 Grant funding of artivities 2024 Support costs 2024 Total funds 2024 Direct patient support 2,889,345 1,460,416 1,314,941 5,664,702 9S

THE BRITISH KIDNEY PATIENT ASSOCIATION TIA KIDNEY CARE UK IA company limited by guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024 12. Analysis of expenditure by activities (continued) Activities urdertaken directly 2023 Grant funding of activities 2023 SupFK)rt costs 2023 Total funds 2023 Direct patient support 2,085,098 1,244,391 1,174,447 4,503,936 Analysis of direct costs Direct patient support 2024 Total funds 2024 Counselling Advocacy Influencing Policy Patient information Other direct SUPFK)rt 157,530 1,376,287 228,250 775,984 351,294 157,530 1,376,287 228,250 77S.984 351,294 Total 2024 2,889,345 2,889,345 Direct patient suptK>rt 2023 Total fLJnds 2023 Counselling Advocacy Influemiry Policy Patient information 193,975 916,214 235,517 645,778 93,614 193,975 916,214 235,517 6￿,778 93,614 Other direct SUPKK>rt Total 2023 2,085,098 2,085,098 Staff c051s comprising wages and salaries, social security costs and wnsion costs are allocated across the different services provided. 96

THE BRITISH KIDNEY PATIENT ASSOCIATION TIA KIDNEY CARE UK (A company limited by guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2W24 12. Analysis of expenditure by activities {continued) Analysis of support costs Direct patient support 2024 Total funds 2024 Governan Finance 193,223 157,757 205,426 170,436 180,738 277,463 129,898 193,223 157,757 20S.426 170,436 1￿,738 27T,463 129.898 Information Technology Human Resources Premises and Facilib'es Cornmunications Grant staff and administration costs Total 2tr24 1,314,941 1,314,941 Direct patient supwrt 2023 Total funds 2023 Governan Finance 171,095 137,965 185,162 139,416 173,699 236,371 130,739 171,095 137,965 185,162 139,416 173,699 236,371 130,739 Information Technolog Human Resources Premises and Facilib'es Communications Grant staff and administration costs Total 2023 1,174,447 1,174,447 Staff costs comprising wages and salaries, social secLJrity costs and tension costs are allocated across the different services provided 13. Analysls of grant funding actlvities Grants to Grant5 to Institutions Individuals 2024 2024 Totsl funds 2024 Grants- patient supwrt 542,795 917,621 1.460,416 97

THE BRITISH KIDNEY PATIENT ASSOCIATION TIA KIDNEY CARE UK (A company limited by guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024 13. Analysis of grant funding activities Icontinuedl Grants to Institutions 2023 Grants to Individuals 2023 Total funds 2023 Grants- pats'ent supwrt 438,226 806,165 1,244,391 Grants bytype 2024 2023 Post funding, projects and equipment Dialysis freedom Small grants Grants to patients Research]Development Mount Cook 385.553 48,496 9,232 917,621 58.025 41,489 302,318 48,420 14,200 806,165 39,688 33,600 Totsl grants 1,4￿,416 1,244,391 98

THE BRITISH KIDNEY PATIENT ASSOCIATION TIA KIDNEY CARE UK (A company limited by guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024 2024 2023 Grants by Instltutlon Alder Hey Children's Hospital Belfast City Hospital British Psy¢hologic81 Society Renal Psychologists SpEoi31 Interest Group Bristol Royal Hospitsl for Children Dialysis Freedom Evelina Children's Hospital Great Ormond Street Hospital for Children Guls Hospital Leeds Children's Hospital Leeds General Infirmary Leeds Teaching Hospital Leicester GerEral Hospitsl Manchester Childrerfs Hospital Manchester Royal Infirmary Mount Cook Newcastle, Freernan Hosytal Nottingham Children's Hospitsl Nottingh3m University Hosptal NHS Trust other grants, including small grants PNNG Paediatric Nephrology Group Queen Alexandra Hospital - Wessex Kidney Cent Qu￿n E11281Elh Birmingham Qu*n's Medical Centre, Nollir¥Jham Queen's University Hospital Belfast Renal Psychological Therapists Renal Social Workers Royal Belfast Hospital for Sick Children Royal Manchester Children's Hospital Shrewsbury and Te￿Ord Hospital NHS Trust Southampton Children's Hospital Southend Hospital - Mid and South Essex Foundation Trust South East Scotland Kidney Pab'ent Association The 8ntish Dietetic Association 4,C￿0 1,140 4,(M)O 1,500 2,500 48,420 3,(K)O 3,(K)O 2,162 7,212 48,496 3,￿0 3.WO 1,256 5,500 2.lJ)O 4,tK)O 3,(X)O 2,￿0 4,￿0 2.lJ)O 41,489 2,￿0 11,710 2.IXIO 70,214 33,600 2,(M)O 3,(X)O 75,088 2,500 1,$00 1.350 10,350 54,814 4,tK)O 4.¢X)O 9.WO 5,000 4,596 4,1X)O 10.754 5,WO 107,(M)2 48,￿0 4,(X)O The Renal Association University Hospital of Wales University Hospital Southampton University of Dert¥ York & Scartorough Teaching Hospital Young Adult Kidney Group ￿A￿GI Lapsed or cawelled grants for prior years 310,677 2,231 3,(K)O 14,534 75,(M)O 1,IX)O 136,0711 (61.503) Total grants to institutions S42.795 438,226 99

THE BRITISH KIDNEY PATIENT ASSOCIATION TIA KIDNEY CARE UK {A cornpany limited by guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024 14. Taxation The Association is a charity and Is entitled to exemption from taxation on rts charit8ble Income 8nd profits virtue of Section 505 of the IncorrE and CorForalion Taxes Act 1988. 15. Auditors. remuneration The auditors. remuneration amounts lo an auditor f￿ of £18,650 Q023 £16,600), and statutory accounts preparation of £2,65012023 - ￿,5001. 16. Staff costs 2024 2023 Wages and salaries Social security costs Pension costs 2.813.306 260.109 221,695 2,058,627 196,691 139,019 3,295,110 2,394,337 The average number of persons employed by the Charity during the year was as follows.. 2024 No. 2023 No. Grants and Fatient aid linduding support costs) Fundraising Advocacy Service Counselling service Policy seNice Management and administration 10 13 38 10 12 22 21 19 91 71 The number of employees whose employee benefits lexclLhJing employer Fension costs) ex￿eded £60,000 was.. 2024 2023 £60k- £70k £70k- £80k £80k- £gOk £100k-£110k The key m8nagemenl personnel of the charity comprise the trustees, the Chief Executive Officer, Policy Director, Director of Marketing aThJ Communications, Finance Director and Director of Patient Supwrt SeNices. The total employee berEfils of the key management Fersonnel of the charity were £426,412 12023. £390,774) and employer Fension contributions £34,28612023. £25,546). 100

THE BRITISH KIDNEY PATIENT ASSOCIATION TIA KIDNEY CARE UK (A company limited by guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024 17. Trustees. remuneration and expenses During the year, no Trustees received any remuneration or other benefils12023 - £NILI. During the year ended 31 DecemtEr 2024, travel exFEnses lotslling £1,024 were reimbursed or paid directly lo 3 Truslees12023 - £2,730 10 3 Trustees). There is a total of £2,78812023'. £2,429) paid by the charity in relation to trustee indemnity insurance on half of trustees. 18. Intangible assets Computer software Cost Additiorts At 31 December 2024 72,273 Amortisation Charge for the year 21 At 31 December 2024 21 Net l)ook value Al 31 December 2024 72,2S2 At 31 December 2023 101

THE BRITISH KIDNEY PATIENT ASSOCIATION TIA KIDNEY CARE UK IA company lirnited by guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024 19. Tangible fixed assets Freehold Flxtures and property fittings Office uipment Total Cost or valuation At 1 January 2024 Additions Diswsals 395,595 105,132 164 127,859 .674 119,1371 828,588 36,838 {19,13n At 31 December 2024 3￿,595 105,296 145,396 646,287 Depreciation At 1 January 2024 Charge for the year On disp)sals 74,648 4.419 S9,9)0 7.683 89,340 27.610 118,1471 223,888 39,712 {18,14n At 31 December 2024 79,067 67,583 98,803 245,453 Net l)ook value Al 31 December 2024 316,528 37,713 $93 400,834 At 31 December 2023 320,947 45,232 38,519 404,698 The Charivs premises were acquired in 2011. The larKI value was £100,000. 102

THE BRITISH KIDNEY PATIENT ASSOCIATION TIA KIDNEY CARE UK IA company limited by guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024 Fixed asset investments Listed investments Cost or valuation At 1 January 2024 Addrtions Disp)sals Revaluatiorts 27,020.575 15.471.873 {17,3S8,681) 1,258,￿0 At 31 December 2024 ,391.767 Net book value At 31 December 2024 26,391,767 At 31 December 2023 27.020,575 Investments at market value comprise: Tolal funds 2024 UK 2024 Overseas 2024 Listed investments 15,866,601 751,940 9,773,226 25,639,V27 761.940 Cash held Lry investment managers Total 2￿4 16,618,541 9,773,226 26,391,767 The historical Gosl of the investments total £23,29),24412023." £18,105, 1691. 2024 2023 Fixed interest 2,931249 5,374,092 19,819,603 18,416,723 502,470 2,090,357 2,385,505 673,733 751,940 465,671 Equities ProFErty Alternatives Cash held by investment managers 26,391,767 27 020,576 103

THE BRITISH KIDNEY PATIENT ASSOCIATION TIA KIDNEY CARE UK IA company limited by guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024 21. Debtors 2023 Due wtthin one year Trade debtors Other debtors 268,310 656,677 327.855 42,671 321,707 199,467 Prepayrnents and accrued income 1.2S2.842 563,845 Creditors: Amounts falling due within one year 2024 2023 Trade creditors Accruals and deferred incow Other taxation and social security Other creditors Grants payatAe 241,057 636,962 57.047 102.348 279,617 268,262 199,406 11,769 22,096 432,308 1,317,031 933,841 Creditors: Amounts falling due after more than one year 2024 2023 Grants payatAe 145.339 146,586 104

THE BRITISH KIDNEY PATIENT ASSOCIATION TIA KIDNEY CARE UK IA company limited by guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024 statement of funds statement of funds - current year Balance at 31 Gainsl December {Lossesl 2024 Balance at 1 January 2024 Transfers inlout Income Expenditure Unrestricted funds Designated funds Designated Funds 26.700,LX)O 1S(M),LK)O) 26,2￿.(1)0 General funds General Fund 431,956 2,711,283 15,316,52n 523,198 2,138,853 4￿,763 Total Unrestricted funds 27.131.966 2.711.283 15.316.627) 23.198 2.138.853 26.688.763 Endowment funds Endowment Fund 90,187 1706 {2,706) 5,506 95,693 105

THE BRITISH KIDNEY PATIENT ASSOCIATION TIA KIDNEY CARE UK IA company limited by guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024 statement of funds Icontinuedl Balance at 31 Gainsl December (Losses) 2024 Balance at 1 January 2024 Transfers inlout Income Expenditure Restricted funds Kidney Machine Children and Young activty breaks 34,882 34,882 15,9)3 15.C#)O 41,311 141,1961 16,018 15.IXIO My Renal Ca Patient Information Exeter arKJ District KPA British Gas Energy Trust Northern Ireland Shared care The Advocacy Officer FLJnd 182,131 10S,CKIO (221,8761 1673) 64,582 13,198 12,9821 10,216 41,414 184,917 5,792 1,600 {155.9321 15,7921 11,b))01 70.399 So,￿0 135,6531 14,347 Hardship, welfare, benefrts 1,(KlO I1.1￿)0) Wales and West - VCMA1 250,250 (250,2501 Safe and Warm - VCMA2 Other 691,035 78,682 {668,5101 19,5651 {22,525) 2,775 71,872 305,303 1,409,567 11,394,356) {23,198) 297,316 Total of funds 27,S27,446 4,123,556 16,713,S891 2,144,359 27,081,772 106

THE BRITISH KIDNEY PATIENT ASSOCIATION TIA KIDNEY CARE UK IA company linited by guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024 statement of funds Icontinuedl statement of funds - prior year Balan￿ at 31 December 2023 Balance at 1 January 2023 Transfers inlout Gainsl (Losses) Income Expenditure Unrestricted funds Deslgnated funds Designated Fund 28,000,(X)o 11,300,000) 26,700,000 General funds General Fund 409 720 2,488,316 15,017,733) 1,3￿￿,034 1,206,619 431,956 Total Unrestricted funds 28,409,720 2,488,316 15,017,733) ,034 1,206,619 27,131,956 EndowTnent funds Endowment FurKi 85,177 2,102 12,1021 5,010 90,187 107

THE BRITISH KIDNEY PATIENT ASSOCIATION TIA KIDNEY CARE UK IA company linited by guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024 statement of funds Icontinuedl Balan￿ at 31 December 2023 Balance al 1 January 2023 ExFenditur Transfers inloul Gainsl (Losses) Incorr Restricted fund5 Kidney Machine Children and Young aclwity breaks My Renal Care Patient Information Exeter and District KPA British Gas Energy Trust 34,882 34,882 51,271 135,3681 15,903 15,000 182,131 15,000 87,200 166,916 171,9851 16,532 13,3341 13,198 148,288 9,208 3,169 178,157 2,(X)O 1106,8741 19,2081 13,1691 1178,1571 12,tK)01 41,414 Northern Ireland Shared care Wales and West Scotland Kidney Kitchen Other 45,034 145,0341 2,775 2,775 198,648 561,784 1410,0951 145,0341 305,303 Totsl of funds 28,693,545 3,052,202 15,429.9301 1,211,629 27,527,446 108

THE BRITISH KIDNEY PATIENT ASSOCIATION TIA KIDNEY CARE UK (A company limited by guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024 statement of funds Icontinuedl Designated funds represent amounts held as tangible fixed assets and sums that the Trustees have set aside lo tE used for the payment of future regularly occurring grants and running costs. These sums are not fully committed al the balance sheet dale and are held as InveslrrEnts to generate Income to facilitate future grant payments. Following a review of the current commitments of the charity, and lakir¥J into account the athice of our investment fund managers, il was agreed that designated fund should reduce lo £26.2￿.0[ following a transfer from designated fund lo the unrestricted fund of £5￿.000. The transfer was made to off-set the impact of the investment movements., the Trustees believe that this is an adequate level required to generate sufficient In￿Me lo cover the regularly occurring grants and running costs, leaving the balance on Operating Furds to te expended over the short term. The Endowment Fund is an erdowmenl re￿iVed from Chris Perrol Critical Illness Trust. The income from the Endowment Fund is also used lo provick holidays for children with kidney problems. The Kidney Machine Fund is from a SFecific legacy bequeathed for the provision of dialysis machims. The Children and Young Activity Breaks Fund relates to specific donations received ty the Charity lo help fund activity breaks for children and young adults. My Renal Care Fund relates to communication supwrt for a larger bid to NHSX ty Wessex Kidney Centre lo promote and develop the MyRenalCare app. The Patient Information FurKJ relates to specific donations received lo help us develop and improve our patient information setvices, ￿ this in the form of webinars, blogs, articles in our magazine Kidney Matters or a brochure. The transfer in the year relates to monies spent on small equiwnent. The Exeter and District KPA Fund exists to financially supwrt kidney patients under the care of the Exeter and Devon based hospitals. The British Gas and Emrgy Trust IBGETI fund relates lo funding ￿0vided ty BGET to set-up and SUPFM)rt our Money arKI Energy Advice service. The money and energy advisors work on a one-to-one basis with people with kidney disease, assessing their needs arKI identifying sources of supwrt lo resolve practi￿1, financial, and psychosocial challenges The Northern Ireland Fund relates lo donations received to suptK)rt kidney patients in Northern Ireland and the Scotland Fund relates to ck)natiorts received lo supwrt kidney patients in Scotland. The Shared Care fLJnd relates lo S￿￿riC donation received to support our Shared Care project The Advocacy Officer Fund relates to specific donations received to fund the Charity's Patient SuptM)rt and Advocacy Service. The Hardship, Welfare and Benefits Fund relates to specific donations received to SUPFK)rt individuals in need. The Wales and West Project relates to the expansion of our Advocacy service within Wales. The project is focused on providing access free, irnpartial guidance and supwrt that centres around welfare with a focus on workn.ng together to help maximise income, redu￿ utility-relaled expenditure and sllp￿rt overall welltEing. The transfer In the year relates to monies stEnt on IT equipment. The Kidney Kitchen Fund relates to Income received specificalty to fund the work arKJ development of patient information related to kne Kidney Kitchen. The Other fund relates to small donations received to SUPPK)rt certain areas of our charitable actwities, we re(x)rd swh donab.ons and related expenditure through this fund. 109

THE BRITISH KIDNEY PATIENT ASSOCIATION TIA KIDNEY CARE UK IA company limited by guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024 Analysis of net assets between funds Analysis of net assets between funds - current period Endowment Restricted Unrestricted funds funds funds 2024 2024 2024 Total funds 2024 Tangible fixed assets Intangible fixed assets Fixed asset Investments 400,834 4CQ,834 72,252 72,252 26,296,074 28.391.767 1,381,973 1,679,289 11,317,031) 11,317,031) 1145,3391 (145,3391 95,693 Current assets Creditors due within one year Creditors dLJe in more than one year 297,316 Total 95,693 297.316 26,688,763 27,081,772 Analysls of net assets betsveen funds - prlor perlod Endowment funds 2023 Restricted Unrestricted funds fLJrKIs 2023 2023 Total funds 2023 Tangible fixed assets Fixed asset Investments 404,698 404,698 26,930,389 27,020,576 877,296 1,182,599 1933,8411 1933,8411 1146,5861 1146,5861 90,187 Current assets 305,303 Creditors due within one year Creditors due in rnore than one year Total 90,187 305.303 27,131,956 27,527,446 110

THE BRITISH KIDNEY PATIENT ASSOCIATION TIA KIDNEY CARE UK (A company limited by guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2W24 Reconcilialion of net nY)vement in funds to nel cash flow from operating activities 2024 2023 Net expEnditure for the ￿[10￿ las KEr Statement of Fin3nGial Actwitiesl 1445.674) 11,166,099) Adjustments for: Depreciation and amortisalion charges (Gainslllosses on investments Dividends, interests and rents from investments Lossllprofitl on the sale of fixed assets Decre8sellinGreasel In deL*ors Iwrease in creditors Exchange IgainslAosses on l￿estrnentS 39,733 33,267 {2,144.359) 11,208,472) 1772,780) 1705,0721 1566) 1688,99n 381,943 351,439 155,938 13,1571 Net cash used in operating activities {3,830,700) 12,542,156) Analysis of cash and cash equivalents 2024 2023 Cash In hand 428,447 751.940 618,754 464,671 Cash held as part of Investments Total cash and eash equivalents 1,178,387 1,083,425 Analysis of changes in net debt At1 January 2024 Cash flows At31 December 2024 Cash at bank and In hand 618.754 464,671 1192,30n 287.269 428,447 751,940 Cash held as part of Investments 1,083,425 94,962 1,178,387

THE BRITISH KIDNEY PATIENT ASSOCIATION TIA KIDNEY CARE UK IA company linited by guaranteè) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024 Contingent liabilities The charity has contingent liabilities in reference lo grants applications that have been received ty Trustees for approval but remain conlingenl upon the applicant's completion. The total amount not re￿gnised in the Financial Statements amount lo £nil12023.' £310,677). Operating lease commitments At 31 DeCeM￿r 2024 the Charity had commitments lo make future minimum lease payments under non- cancellable operating leases as follows.. 2024 2023 Other Not18ter than 1 ye8r Later than 1 year ard not later than 5 years 2,194 7,127 2,285 1,815 9,321 4100 2024 2023 Land and Buildings Not later than 1 ye8r Later than 1 year aThJ not later tran 5 years Za.(￿7 14,047 28,000 37,333 37,114 65.333 OFÉrating lease rentals recognised as an expense in the Statement of financial activities were £28,425 12023.. £29,922) 31. Related party transactlons In the year, donations received from trustees lotalled £6,67212023." £3,568) 112

THE BRITISH KIDNEY PATIENT ASSOCIATION TIA KIDNEY CARE UK (A company limited by guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024 Prior year statement of financial activities Endowment funds 2023 Restricted Unrestricted funds funds 2023 2023 Total funds 20Z3 Income and endowments from: Fknnatiorts and legacies Charrtable actlmlies 383.627 178.157 1,723.983 2.107.610 178.157 55.122 711,313 3,052,202 other tr&ing 8CtiMties Invèstments 55,122 709.211 2,488.316 2.102 2.102 Total income and endowments 561.784 Expenditure on: Raising funds Charrtable actimlies 72 925.922 4,091.811 5,017.733 25.994 4.503,936 5,429.930 2.030 2.102 410.095 410.095 Total expenditure Net income I (expenditure) before net {los** I gains on investsnents 151.689 12,529,417) (2,377.7281 1,2(￿.619 1.211,629 11,322,798) {1,166,0991 45.034 11,277.764) (1.166,0991 Net Ilossesl I gains on in￿StMentS Net income I lexpendffcurel Transfers LEtween funds Nel movement in funds 5.1710 5,010 151,689 145.034) 1￿.655 5.010 Reconciliation of funds: Total funds br￿ght fopNard Net moKemenl in funds 85.177 5.IMO 90,187 198.648 1￿.655 305,303 28,409.720 28.693,545 11,277.764) 11,166,099) 27,131,956 27,527,446 Total funds carried forward 113

Kidney Care UK is the UK’s leading kidney patient support charity, providing practical, financial and emotional assistance for kidney patients and their families throughout the UK. We believe that no one should face kidney disease alone.

For further details of all the support we provide to people living with kidney disease, please visit our website www.kidneycareuk.org or call us on 0808 801 00 00

www.kidneycareuk.org | info@kidneycareuk.org 01420 541 424 | Lines open 9am - 5pm, Monday–Friday Kidney Care UK, 3 The Windmills, St Mary’s Close, Alton, GU34 1EF

©Kidney Care UK. Kidney Care UK is the operating name of the British Kidney Patient Association. A charitable company limited by guarantee. Registered in England and Wales (1228114). A charity registered in England and Wales (270288), and Scotland (SCO48198).